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 ABSTRACT 
 In order to investigate the structural features responsible for the cytotoxicity of the 
naturally occurring lignan nordihydroguaiaretic acid, the synthesis of four structural analogues of 
NDGA was proposed for the purpose of studying their oxidative metabolism.  One analogue in 
particular (1), a mono-catechol analogue, was successfully synthesized employing a double 
Stobbe condensation approach.  Following synthesis of this compound a series of oxidation 
experiments was performed consisting of: incubation in rat liver microsomes with and without 
the trapping agent glutathione (GSH), oxidation with mushroom tyrosinase, oxidation with silver 
oxide, and oxidation with horseradish peroxidase.  Results were analyzed via HPLC and UPLC-
MS.  It was found that 1 does not autoxidize at pH 7.4 as NDGA does.  Two products were 
produced during incubation of 1 in rat liver microsomes with UPLC-ESI(-)-MS results giving 
m/z of 879.23 and 574.18.  This is consistent with 1 plus 2 GSH and 1 plus 1 GSH respectively; 
confirming 1 will oxidize to an electrophilic moiety.  Oxidation with mushroom tyrosinase was 
found to produce high levels of the product with m/z 574.18.  Oxidation with horseradish 
peroxidase is found to produce high levels of the m/z 879.23 product.  Silver Oxide produced 
multiple products rather than the expected one major product, but most were found to be 
inconsistent with the products seen during rat liver microsomal incubation, and were not 
pursued. 
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 1.0 INTRODUCTION 
1.1 Nordihydroguaiaretic Acid 
1.1.1 Natural Occurrence: the Creosote Bush 
 Nordihydroguaiaretic acid is a naturally occurring lignan produced by the creosote bush, 
Larrea tridentata (Figure 1-1).  This bush is a common flowering shrub found in arid regions of 
the south-western United States and northern Mexico.  Considered to be the most abundant 
secondary metabolite of L. tridentata1, NDGA has been found in amounts between 5-15% by dry 
weight in the leaves and twigs of the bush 2, 3.  
OH
OH
HO
HO  
Figure 1-1: Structure of Nordihydroguaiaretic Acid (NDGA) 
 
1.1.1.1 Medicinal Uses of the Creosote Bush   
The creosote bush has a long, varied history of medicinal uses, in particular among the 
native peoples indigenous to the area2.  More than 50 documented illnesses and afflictions are 
treated with different preparations of the creosote bush1-5, including gallbladder and kidney 
stones, urinary tract infections and type II diabetes.  It is most commonly administered as an 
aqueous extract prepared by boiling the leaves and twigs, which is then sipped throughout the 
day.  Externally, prepared salves are administered to treat burns, chicken pox, and snakebite 
pain.  These external preparations are thought to be particularly useful due to the reported 
antibiotic, antiviral, and antifungal properties of the creosote bush extract 2, 6.  More recently, 
creosote bush extract has been made available in tablet form as the natural supplement 
Chaparral.  It was also reported as a component of the herbal product Herp-EezeTM, marketed as 
a treatment for Herpes simplex infection1. 
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 1.1.2 Pharmacological Properties of NDGA 
 NDGA has been found to possess a number of potentially useful pharmacological 
properties.  In 2004, Lambert et al.1 reviewed a number of these biological activities, including 
NDGA as an effective cancer chemopreventative agent, NDGA’s ability to inhibit the growth of 
a number of cancer types in vitro and in vivo, the fertility-regulating effects of NDGA, and the 
hypoglycemic activity of NDGA in both rat and mouse models of type II diabetes.  The NDGA 
product Actinex® was also used as a topical medication for the treatment of the skin condition 
actinic keratoses for a short period of time.  However, following the emergence of skin 
hypersensitivity in patients, it was removed from the market3, 7. 
1.1.3 Other Properties of NDGA   
NDGA is a known antioxidant, preventing the propagation of lipid peroxyl radical 
reactions by forming stable radicals and by-products.  It is also a known inhibitor of the 
lipoxygenase and cyclooxygenase pathways2, 6, 8.  Its antioxidant capacity was exploited for a 
short time in preserving fats and butter, but is currently only used as an antioxidant in the storage 
of natural and synthetic rubber2, 3, 9, 10. 
1.1.4 Toxicity of NDGA 
The withdrawal of NDGA as a food preservative was a result of a number of studies 
released in the late 1960s and early 1970s linking the ingestion of NDGA to the formation of 
cysts in the kidney9, 10.  Goodman et al. reported that a 3% NDGA diet fed to 24 rats over a 15 
day period resulted in the death of 7 animals.  Significant weight loss and cystic structures were 
found over the entire surface of the kidneys in the animals studied.  In 2002, Lambert et al.3 
determined the lethal intraperitoneal dose of NDGA in mice to be LD50=75 mg/kg.  Significant 
weight loss in the test animals was observed, and on high dosing with NDGA (100 and 500 
mg/kg), 100% mortality was observed within 30h of administration. 
Hepatotoxicity has also been associated with prolonged overexposure to creosote bush-
based products such as chaparral.  Chronic consumption of chaparral in humans has resulted in 
patients suffering from toxic or drug-induced hepatitis 2, 5.  Upon cessation of ingestion of these 
products, the damage is most often found to be reversible and non-permanent.  In some cases, the 
damage progressed to cirrhosis of the liver2, 5, and in fewer cases, total hepatic failure was 
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 reported and liver transplantation was necessary2, 5, 8.  In one particular case, a patient not only 
suffered hepatic failure, but also renal failure which was attributed to the prolonged consumption 
of creosote bush products2, 5. 
1.1.5 NDGA Quinones 
The cytotoxicity attributed to NDGA is thought to be due to its oxidized ortho-quinone 
form (Scheme 1-1), a reactive intermediate that can be produced in vivo on metabolism of 
NDGA10, 11.  
 
Scheme 1-1: Oxidation of NDGA from the Catechol to the Ortho-Quinone 
 
 The toxicity of the o-quinone has two mechanisms: first, alkylation of cellular 
macromolecules via conjugate addition, which can result in alteration of nucleotide sequence in 
the case of DNA, or the disruption of tertiary and quaternary structure in the case of proteins; 
second, redox cycling, which produces reactive oxygen species that can oxidize essential cellular 
components (Scheme 1-2)12. 
 
Scheme 1-2: Oxidation of a Catechol to an o-Quinone and Resulting Mechanism of Cytotoxicity 
 
 One other product is possible in the oxidation of catechols which possess at least one 
benzyl proton, and that is the para-quinone methide (QM).  The p-QM can be formed directly 
from the catechol itself, or from the o-quinone as a tautomer11, 13(Scheme 1-3).  The rate at which 
the o-quinone tautomerizes to the p-QM is impeded by increased substitution at the benzyl 
position12.  This subsequently leads to the prediction that NDGA, possessing a methylene group 
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 at the benzyl position, would isomerize to the p-QM slowly11.    The p-QM is known to be much 
more electrophilic than the o-quinone, and consequently participates in the alkylation of cellular 
nucleophiles14, 15, and redox reactions are found to be uncommon12, 14. 
 
Scheme 1-3: Conversion of NDGA to the p-QM. 
 
1.1.5.1 NDGA Oxidation Experiments 
Oxidizing a catechol with tyrosinase as a catalyst is a common method of producing the 
o-quinone moiety14.  It has been found that NDGA can be successfully oxidized to its o-quinone 
form using the enzyme mushroom tyrosinase, with the resulting products trapped as adducts with 
glutathione (GSH).  Three NDGA-GSH adducts were isolated and identified (Scheme 1-4)11. 
 
Scheme 1-4: Trapping the o-Quinone of NDGA with Glutathione 
 
  A common method of producing the p-QM form of a catechol is to oxidize with Ag2O, 
and trap the resulting electrophilic entity with GSH as per the example shown in Scheme 1-512.   
In order to assess the possibility of the p-QM contributing to the toxicity of NDGA, attempts 
were made to produce the p-QM via oxidation using Ag2O, trapping the resulting product with 
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 GSH.  The UV spectrum (λmax=360 nm) was consistent with the formation of quinone products; 
however, this method failed to produce GSH-QM adducts, and no GSH active products were 
produced (Scheme 1-6)11.  It is unclear why oxidation of NDGA with Ag2O did not result in the 
formation of GSH-QM adducts.    
 
Scheme 1-5: Oxidation of 4-Propyl Catechol to the p-QM using Ag2O 
 
 
Scheme 1-6: Attempted Oxidation of NDGA to the p-Quinone Methide 
 
 The products obtained in these enzymatic and chemical oxidation experiments were 
compared to the products obtained when NDGA was incubated in rat liver microsomes for 60 
min at pH 7.4, an in vitro experiment often used to investigate the potential formation of reactive 
metabolites for a given compound.  It was determined that the o-quinone formed, and in the 
presence of GSH, all three adducts as seen in Scheme 1-4 were produced.  Control microsomal 
incubations performed in the absence of NADPH, or in the presence of heat inactivated 
microsomes were also found to produce the same GSH adducts.  This result suggests that the 
formation of the o-quinone at pH 7.4 is not cytochrome-P450 (P450) dependent, and that NDGA 
is undergoing autoxidation, which is an observation consistent with previously reported research 
on NDGA16.  On further investigation, it was determined that the autoxidation of NDGA is a 
base-catalyzed process from pH 6.0 to 9.0, and the half-life of NDGA at pH 7.4 is 3.1 h11.  This 
rate of autoxidation is faster than that for a number of catechols, such as catechol and 
dopamine11. 
 When NDGA was incubated at pH 7.4 in the absence of the trapping agent GSH, a small 
amount of the o-quinone was observed via LC-MS, along with a hydroxylated form of NDGA.  
The major product however was found to be a schisandrin-like dibenzocyclooctadiene lignan 
(Figure 1-2), likely formed by intramolecular cyclization of NDGA, possibly via a radical 
intermediate11.  Given that many systems used to investigate the biological activity of NDGA are 
performed at or near pH 7.4, and furthermore that native healers traditionally extract the leaves 
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 and twigs of the creosote bush by boiling in water, it is possible that a significant number of the 
pharmacological properties attributed to NDGA are in part due to the stable 
dibenzocyclooctadiene lignan 17.  This is speculation on the part of the authors. 
 
Figure 1-2: NDGA Derived Dibenzocyclooctadiene Lignan 
 
1.2 Synthetic Analogues of NDGA 
In an attempt to better understand these oxidative properties of NDGA, such as why 
NDGA does not form p-QM-GSH adducts, and what factors contribute to the rapid autoxidation 
of NDGA, the synthesis of four NDGA analogues (Figure 1-3) has been proposed for the 
purpose of studying their oxidative metabolism. 
HO
HO
H3CO
HO
OH
OCH3
1 3
H3CO
HO
HO
HO
OCH3
OCH3
2 4  
Figure 1-3: Proposed Synthetic Analogues of NDGA 
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 1.2.1 Synthetic Methods 
A number of methods for synthesizing lignan analogues exist in the literature.  Six 
possibilities were reviewed and considered as potential pathways to the desired analogues.  Four 
of the methods involved coupling two phenylpropanoid units; a fifth involved an imprecise 
methylation of existing aromatic hydroxyl groups.  Ultimately, the method chosen to pursue 
involved two consecutive Stobbe condensation reactions to form the lignan skeleton. 
1.2.1.1 Method 1: Grignard Reaction  
 It was expected that all four analogues could be prepared via Grignard reaction (Scheme 
1-7)18. 
 
Scheme 1-7: Preparation of Analogue 1 via Grignard Reaction 
 
 The alkene produced in the dehydration step would theoretically result in a mixture of Z 
and E isomers (E isomer shown).  Following hydrogenation of this mixture of alkenes, the 
resulting products would be a mixture of stereoisomers19.  From the reaction for each of 
analogues 1, 2 and 4, four stereoisomers should result, consisting of two pairs of enantiomers 
(Figure 1-4).  From the reaction for analogue 3, three stereoisomers should be present consisting 
of one pair of enantiomers and one diastereomer (Figure 1-4).  Chromatographic separation of 
diastereomers should be possible19. 
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Figure 1-4: Possible Isomers for Analogues 1, 2, 3 and 4 Following Alkene Hydrogenation 
 
Reaction yields reported in the literature from which this scheme was derived include 
individual reaction yields for each step between 70-85%, with an overall yield between 45-
54%18.  Previous unpublished work from the Krol group suggests that the first step in this 
particular method has a low yield for the synthesis of analogue 1. 
1.2.1.2 Method 2: β-β Coupling with Alkaline Potassium Ferricyanide 
 This particular coupling reaction would only be successful in the synthesis of the 
symmetrical analogue 3 (Scheme 1-8).   
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Scheme 1-8: Synthesis of Analogue 3 via β-β Coupling Reaction 
 
 The key step to producing the lignan skeleton in this method is a β-β coupling reaction 
performed with alkaline potassium ferricyanide in a two-phase benzene-water system19.  Prior to 
this step, it is crucial to block the 5-position on the aromatic ring with a t-Bu group to eliminate 
the formation of the β-5 coupling product, which was reported to be the main product when the 
5-position was left exposed19.  Protection of the aromatic hydroxyl group does not appear to be 
necessary. 
Yields reported in the literature for individual reactions range from 49%-99%19.  The 
second hydrogenation performed on the diene-diester entity is anticipated to give the three 
stereoisomers as seen above in Figure 1-4. 
1.2.1.3 Method 3: McMurry Coupling 
 The McMurry coupling reaction would only be successful in producing the symmetric 
analogue 3 (Scheme 1-9).  This method was reported by Gezginci et al. in 20017 as a synthetic 
way to produce NDGA.   
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Scheme 1-9: McMurry Coupling Reaction, Analogue 3 
 
A similar reaction sequence was attempted by me as part of my University of 
Saskatchewan chemistry 483.6 project in 2005/06.  At that time, the starting material employed 
was 4-benzyloxy-3-methoxyphenylacetone, utilizing a benzyl protecting group for the aromatic 
hydroxyl.  The TiCl4/Zn coupling reaction was not successful with this compound, and the 
expected diol was never obtained.  Given that the 3,4-dimethoxyphenylacetone coupling reaction 
was indeed successful when performed by me, it was theorized that perhaps the benzyloxy group 
was too electron-withdrawing in comparison to the methoxy group, and a different protecting 
group may be required for a successful coupling reaction.  Trimethylsilyl ether is shown as the 
protecting group in Scheme 1-9, but could be replaced by tert-butyldimethylsilyl ether as an 
alternate protecting group. 
 Both the Z and E isomers of the alkene would be expected to form on dehydrogenation of 
the diol, and the hydrogenation product is expected to consist of two enantiomers and one 
diastereomer. 
 Yields were not fully reported in the literature, and included a 4:6 mixture of the Z:E 
alkene mixture with an overall yield of 65%.  The diol product yield was reported as 73%7. 
1.2.1.4 Method 4: Grignard Reagent Dimerization 
 Often considered to be the unwanted side-product in a Grignard reaction, the Grignard 
reagent dimerization reaction could provide a route to analogue 3 (Scheme 1-10).  This reaction 
scheme was adapted from Lieberman et al.20. 
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Scheme 1-10: Grignard Reagent Dimerization to Produce Analogue 3 
 
 A yield of only 30% was reported in the literature for this method20.   
 It is unclear what, if any, stereoselectivity may result from the Grignard reagent 
dimerization reaction.  Three diastereomers, including a pair of enantiomers, could be possible. 
1.2.1.5 Method 5: Methylation 
 The strategy of methylating pre-existing hydroxyl groups was reported in 1998 by Hwu 
et al.21 (Scheme 1-11).  This method could be successful in producing analogue 3 and 4.  In the 
case that analogue 1 happens to be easily synthesized, analogue 2 could possibly be formed from 
analogue 1 with this method.   
 
Scheme 1-11: Reaction of NDGA with Dimethyl Sulfate to give a Mixture of Nine Methylated Products21. 
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  This method is not specific, and could possibly result in a mixture of products that may 
be difficult to separate.  Of these nine products, only ‘meso-4’ and ‘(±)-6’ are desired 
compounds for this study.  The maximum yield reported for all di-methylated products, 4, 5 and 
6, is 28%21, with conditions consisting of 1.0 equivalent of Me2SO4 and 4.9 equivalents of 
K2CO3. 
1.2.1.6 Method 6: Stobbe Condensation 
 This synthetic scheme was adapted from Xia et al.22.  It was selected based on the fact 
that all four analogues could theoretically be prepared via this method.  The details shown in 
Scheme 1-12 outline the synthesis of Analogue 2. 
 
Scheme 1-12: Preparation of Analogue 2 via Stobbe Condensation 
i) a : EtONa, diethylsuccinate, reflux, 4h ; b : H2O, NaOH, reflux, 2h ; ii) EtOH, THF, reflux, 24h ; iii) a) 
EtONa, benzaldehyde, 0°C, 24h ; b : H2O, NaOH, reflux, 2h ; iv) EtOH, THF, reflux, 36h ; v) H2, Pd/C (10%) ; 
vi) LiAlH4, THF, reflux ; vii) TsCl, pyridine, CH2Cl2 ; viii) LiAlH4, THF, reflux ; ix) KOH, EtOH-H2O, reflux, 10 h. 
 
 Individual reaction yields reported in the literature range from 73-99%22.   
 Hydrogenation of the double bonds (step v) is anticipated to result in a number of 
different stereoisomers, as per Figure 1-4 above: four isomers for analogues 1, 2 and 4 consisting 
of two pairs of enantiomers, and three diastereomers including one pair of enantiomers for 
analogue 3. 
1.2.1.6.1 The Mechanism and Stereoselectivity of the Stobbe Condensation 
 The specific case of the condensation of diester succinates with ketones was identified as 
unusual in 1893 by Hans Stobbe when the reaction between diethyl succinate and acetone gave a 
product that was inconsistent with the expected Claisen-type product.  An extensive study of this 
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 reactivity ultimately showed that aldehydes and ketones generally reacted in this manner with 
diester succinates23. 
 Diethyl succinate is found to react more readily with weaker bases such as sodium 
ethoxide, and is considered to have a higher reactivity than even that of malonates, as indicated 
by its ability to react with benzophenone, which is absent in malonates under similar conditions.  
This reactivity is thought to be due to the mechanism of the Stobbe condensation (Scheme 1-13).  
This mechanism is widely believed to include an intramolecular cyclization involving the 
intermediate oxyanion which results in the formation of a 5-membered lactone23-26.  Evidence for 
the formation of this intermediate is supported by the isolation of the lactone product, 
particularly during shorter reaction times23.  Furthermore, only the alkene is produced during the 
Stobbe condensation reaction via β-elimination on cleavage of the lactone, and the alcohol has 
never been isolated.  This proposed mechanism also explains the formation of the carboxylic 
acid product rather than the di-ester product. 
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Scheme 1-13: Mechanism of the Formation of the 5-Membered Lactone and Subsequent β-Elimination 
During a Stobbe Condensation Reaction between Diethyl Succinate and an Aldehyde 
 
 It has been noted that in the case of the formation of the lignan skeleton by way of the 
double Stobbe condensation, as considered here, the mechanism of the second condensation 
reaction is also thought to proceed by way of the intermediate lactone, which is again supported 
by the isolation of this intermediate product at lower temperatures. 
 The stereochemistry of the double bond that is formed during the β-elimination step 
following the condensation of an aromatic aldehyde with diester succinate has been found by a 
number of groups to be stereoselective, giving only the E configuration 25, 26.  The E or Z 
configuration of these compounds can be differentiated by 1H NMR studies.  It has been found 
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that the olefinic proton in the E configuration appears beyond 7.5ppm, downfield from the Z 
proton by approximately 0.5-1.0ppm 25, 26.  This shift is due to the deshielding effect of the 
carbonyl group 26.    
The preference of the Stobbe condensation to form only the E  isomer is due to a 
stereoelectronic effect originally described as the result of a mechanism involving ‘overlap 
control’26, as proposed by Zimmerman et al.27 to explain the stereoselectivity of carbanionoid 
reactions, and in particular, the Perkin reaction.  This overlap control mechanism includes the 
stabilization of the negative charge which is formed on the tertiary carbon following proton 
extraction by the alkoxide (Scheme 1-13), by delocalization to the oxygen atom of the ethyl 
ester26.  This results in a favourable anti-periplanar transition state that does not result in any 
eclipsing effects between the aromatic system and the ester groups, and allows for maximum 
overlap of the developing π-orbitals (Scheme 1-14)25, 26. 
 
Scheme 1-14: Conformation of the Stobbe Intermediate 
 
The stereochemistry of the double bond formed during the second Stobbe condensation 
has not been reported in the literature as often as the first.  Anjaneyulu et al.25 reported the E,E 
configuration only in the synthesis of dibenzylidene succinic anhydrides via double Stobbe 
condensation.  These structures were again determined by 1H NMR, with both olefinic protons 
appearing downfield of what would be the Z proton.  It is worth noting that in the case of a 
symmetrical compound, the olefinic protons appeared as a single peak25.  
 2.0 HYPOTHESES 
1. Autoxidation of mono-catechol lignan 1 will be significantly slower than that of NDGA, 
a di-catechol. 
2. Mono-catechol analogue 1 of NDGA can form an o-quinone. 
3. Mono-catechol analogue 1 of NDGA can form a p-QM either directly, or as a result of o-
quinone isomerization. 
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3.0 OBJECTIVES AND AIMS 
3.1 Synthesis of NDGA Analogues 
 Method 6, which included two consecutive Stobbe condensations to form the basic lignan 
skeleton, was chosen as the primary method for the synthesis of analogue 1.  This method 
provides the greatest flexibility for producing a variety of analogues beyond 1, and also provides 
the option of isolating a diol intermediate which may have other applications within the lab 
group.  A number of pilot reactions were performed on the compound eugenol in order to 
attempt the addition and removal of protecting groups which were to be used during the 
synthesis.   
3.2 Determination of the Metabolites of the Lignan Analogues: In Vitro 
Microsomal Incubation 
 In vitro microsomal studies are a common method used in metabolic studies of new drug 
candidates.  In order to determine the likelihood of synthetic analogue 1 forming reactive 
intermediates, the lignan is incubated at 37°C for one hour in rat liver microsomes with an 
NADPH-generating system and GSH to study the products of P450-mediated metabolism.  
Control reactions include lignan in buffer, lignan in buffer with GSH, a system without NADPH, 
a system which includes only heat inactivated microsomes, and a system without GSH. The 
products are identified via HPLC and electrospray mass spectrometry. 
3.3 Oxidation of the Lignan Analogues using Chemical and Enzymatic 
Methods 
 In order to accurately determine which of the possible metabolites are formed during 
microsomal incubations, preparation of the reactive quinone intermediates is necessary.  
Analogue 1 can be oxidized to the corresponding p-QM using silver oxide in acetonitrile 
 (Scheme 3-1)12.  The reactive quinone is trapped with GSH in buffer, and the GSH adduct 
analyzed via LC-MS. 
 
Scheme 3-1: Formation of Quinone Methide and Potential GSH Product of Analogue 1 
 
 Analogue 1 is also oxidized using the enzyme tyrosinase, and the enzyme horseradish 
peroxidase, and the resulting o-quinone is trapped using GSH (Scheme 3-2).  LC-MS can be 
used for product identification. 
 
Scheme 3-2: Formation of o-Quinone and Potential GSH Products of Analogue 1  
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 4.0 EXPERIMENTAL 
4.1 Materials 
The following chemicals were obtained from Sigma-Aldrich (St. Louis, MO): eugenol, 
3,4-dimethoxy benzaldehyde, benzaldehyde, vanillin, 3-hydroxy-4-methoxybenzaldehyde, 
diethyl succinate, Pd/C, DMSO d6, anhydrous DMSO, benzyl bromide, 3,4-
dihydroxybenzaldehyde, BBr3 (1 M in DCM), LiAlH4, anhydrous pyridine, MgCl2, GSH, 
NADPH, salicylamide, mushroom tyrosinase, horseradish peroxidase, Ag2O, p-toluenesulfonyl 
chloride, Mg turnings, anhydrous THF, anhydrous DCM, molecular sieves 3A, iodomethane.  
Ethanol, which was distilled and stored over sieve under N2(g) prior to use, was obtained from 
Commercial Alcohols Inc. (Brampton, ON).  CDCl3, MeOD, and DMSO d6 were obtained from 
Cambridge Isotope Laboratories Inc. (Andover, MA).  All other solvents were of the highest 
grade purity, obtained from EMD (Gibbstown, NJ).  Celite® 545 and silica gel 60 (0.040-0.063 
mm) used in flash columns was also obtained from EMD.  Benzyl bromide, NaCl and NaOH 
were obtained from Fluka Chemika (Switzerland).  K2CO3, NaHCO3, HCl, H2SO4, Na2HPO4, 
KOH, and perchloric acid were all obtained from BDH Chemicals (Toronto).  H3PO4 and the sea 
sand used in the flash columns were obtained from Fisher Scientific (Fairlawn, NJ).  MgSO4 was 
obtained from JT Baker Inc. (Phillipsburg, NJ).  Anhydrosecoisolariciresinol (ASECO) was 
prepared and provided by J. L. Billinsky (University of Saskatchewan) as outlined below.  
NaOEt solution in ethanol was prepared by addition of Na(s) to dry ethanol.  
4.1.1 Preparation of Rat Hepatic Microsomes 
Male Sprague-Dawley (S-D) rats were purchased from Charles River Laboratories, Inc. 
(Saint-Constant, PQ) at approximately 200-250g or 13 weeks of age (~150g).  Rats were housed 
in a temperature, humidity and 12 hour light-dark controlled facility at the College of Pharmacy 
and Nutrition, University of Saskatchewan.  Rats were allowed to acclimatize in the facility for 
at least one week and were fed standard laboratory rat chow, ad libitum and had free access to 
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 water. All procedures were approved by the University Committee on Animal Care and Supply 
at the University of Saskatchewan.  Rats (n=4) were anesthetized with isoflurane and a midline 
incision made to expose the abdominal cavity. The portal vein was isolated and cannulated with 
a 20g 1¼” Terumo Surflo I.V. catheter. The vena cava was nicked to allow blood and perfusate 
outflow. The livers were perfused via the portal vein with room temperature phosphate buffered 
saline (PBS) until the liver cleared and no blood was visible exiting the vena cava. Livers were 
removed and rinsed in PBS. Livers were weighed into 3 or 6 g pieces 33 and immediately flash 
frozen in liquid nitrogen and stored at -80°C until microsomal preparation.  Microsomes were 
prepared by differential centrifugation according to the method of Iba et al.28.  Briefly, tissues 
were homogenized with a teflon pestle in a glass sleeve in homogenization buffer (0.1 mM 
phenylmethylsulfonylfluoride, 50mM Tris buffer, 150 mM KCl, 0.1 mM dithiothreitol, 1 mM 
ethylenediamine tetracetic acid and 20% glycerol) until homogeneous. The mixture was 
transferred to a Beckman (Beckman Coulter Canada, Inc. Mississauga, ON) ultracentrifuge tube 
and spun in a Beckman L8-55 Ultracentrifuge with a Ti-70 rotor at 9000g for 30 minutes at 4°C. 
The supernatant, which contains both cytosolic and endoplasmic reticulum components, was 
transferred into clean ultracentrifuge tubes and spun at 100 000g for 30 minutes at 4°C. The 
pellet was washed with 150 mM KCl then similarly spun for an additional 30 minutes at 4°C.  
The pellet was reconstituted in 0.25 M sucrose and passed through a syringe. The microsomes 
were pooled (n = 4) at this point and stored at -80°C. Samples were only used after one thaw. 
4.1.1.1 Determination of Hepatic Microsomal Protein and Cytochrome P450 
Content  
Microsomal protein content was determined by the method of Lowry et al.29.  Briefly, 
microsomes were diluted 1:50 in 0.5 M NaOH. To samples containing 0, 0.2, 0.4, 0.6 0.8 or 1.0 
mL diluted microsomes (final volume 1 mL with 0.5 M NaOH) 5 mL of copper reagent (0.01% 
copper sulphate, 0.02% sodium potassium tartrate, 99.97% sodium carbonate) was added. After 
10 minutes, 0.5 mL of Folin’s reagent (1:2 dilution with H2O) was added and samples stood for 
an additional 30 minutes.  Absorbance was determined in a UV/Vis spectrophotometer (#8453E, 
Agilent Technologies, Palo Alto, 34 CA) at 750 nm. Samples were compared to a similarly 
prepared bovine serum albumin standard curve to determine protein content. Cytochrome P450 
content was determined using the method of Omura and Sato30. Microsomes were thawed on ice 
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 and diluted to 1 mg/mL in a quartz cuvette. A few mg of hydrosulphite was added and CO gas 
bubbled at a rate of three bubbles per second for 30 seconds. From absorbance measurements at 
420, 450 and 490 nm in an UV/Vis spectrophotometer, the CYP content was determined. 
4.2 Equipment 
TLC aluminum sheets used were silica gel 60 F254 purchased from EMD Chemicals Inc. 
(Gibbstown, NJ).  Rotary evaporator systems used were Büchi Rotavapor R-200, and Büchi v700 
vacuum pump with attached v850 vacuum controller.  The Eppendorf Concentrator 4301 with 
Büchi Vac V-500 with attached v850 vacuum controllers was used to concentrate samples in 
tubes.  Trace amounts of solvent and moisture were removed using an Edwards High Vacuum 
Pump.  Vacuum filtration and flask evacuation for hydrogenation was performed using a Gast 
pump (Benton Harbor, MI).  Vortexed reactions utilized a Janke & Kunkel IKA-Vibrax VXR 
with VX2 attachment.  Incubations took place in a Boehel Grant ORS 200 shaking heating water 
bath.  All water used was purified via a Millipore Milli-Q system with a Quantum EX Cartridge 
(Mississauga, ON).  Samples were centrifuged in an Eppendorf centrifuge 5417C.  HPLC system 
used was the Waters Alliance 2695.  Analytical column was 250mm x 4.6mm Allsphere ODS-2 
5u Alltech column (Deerfield, IL).  The HPLC system was controlled by, and data interpreted 
with the Waters Empower software.  The UPLC-MS system was a Waters Acquity 
Synapt HDMS system with Waters Acquity PDA and Synapt Q-TOF.  The Column was a 
Waters BEH C18 1.7 micron 2.1 x 50 mm column, with the data analyzed on Masslynx 4.2 
software.  All NMR experiments were performed on a Bruker AVANCE DPX-500 spectrometer, 
with all data processed by X-WIN NMR 3.5 software.  All compounds were named using 
ChemDraw Ultra.  
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 4.3 Methods 
4.3.1 Pilot Reactions: Eugenol 
4.3.1.1 1-Allyl-3,4-dihydroxybenzene (5)14 
 
 
5 
 To a stirring solution of (CH3)2S•BBr3 (3.8 g, 12.2 mmol) in DCM (35 mL) under N2(g) 
was added dropwise 0.50 g (3.0 mmol) of eugenol, and the reaction mixture refluxed 2 h.  The 
reaction was hydrolyzed with 10 mL H2O and diluted with ether.  The organic phase was 
separated and washed with NaHCO3, and extracted with 1 M NaOH.  The combined NaOH 
extracts was acidified, extracted with ether, and dried over MgSO4.  The resulting solvent was 
concentrated under vacuum, and the residue chromatographed over Si gel (25:1 CHCl3:MeOH) 
(0.13 g, 0.84 mmol, 28%). 
4.3.1.2 4-Allyl-1-(benzyloxy)-2-methoxybenzene (6)31 
 
6 
To a stirring solution of eugenol (0.50 g, 3.0 mmol) in EtOH (12 mL) under N2(g) was 
added K2CO3 (0.63 g, 4.6 mmol) and BnBr (0.52 g, 3.0 mmol).  The reaction was stirred 
overnight for 20 h.  The mixture was filtered through celite, and the filtrate diluted with EtOAc 
(50 mL).  The organic layer was then washed with 1 M H3PO4 (60 mL) and saturated NaCl (3 x 
50 mL) solution, and dried over MgSO4.  The resulting solution was concentrated under vacuum, 
and the residue chromatographed over Si gel (8:1 hexane: ethyl acetate) via flash column.  Final 
product was a yellow liquid (0.62 g, 2.4 mmol, 80%).  1H NMR (CDCl3) δ 3.37(d, 2H), 3.91(s, 
3H), 5.11 (m, 2H), 5.17 (s, 2H), 6.00 (m, 1H), 6.71 (d, 1H), 6.78 (s, 1H), 6.85 (d, 1H), 7.33 (t, 
1H), 7.40 (t, 2 H), 7.48 (d, 2H). 
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 4.3.1.3 2-Methoxy-4-propylphenol (7)12 
 
7 
To a stirring solution of 6 (0.54 g, 2.1 mmol) in ethanol (20 mL) was added Pd/C (10%) 
and 3 drops of TFA.  The flask was evacuated and flushed with H2(g) several times once it had 
been stoppered and sealed tightly.  The mixture was stirred under H2(g) at room temperature for 
26 h.  The reaction mixture was then filtered through Celite and concentrated under vacuum.  
Final product was a dark yellow oil (0.35 g, 2.10 mmol, 99%).  1H NMR (CDCl3), δ 0.96 (t, 3H), 
1.63 (sextet, 2H), 2.54 (t, 2H), 3.89 (s, 3H), 6.70 (d, 2H), 6.85 (d, 1H).  
4.3.1.4 4-Propylbenzene-1,2-diol (8)18, 32 
 
8 
A stirring mixture of 7 (0.22 g, 1.34 mmol) in anhydrous DCM (13 mL) under N2(g) was 
cooled to -78°C.  BBr3 (3.35 mL of 1 M in DCM) was then added to the solution via syringe and 
stirred for 2 h.  The solution was then warmed to room temperature, and the reaction quenched 
with H2O (66 mL) and extracted with EtOAc (1 x 30 mL, 2 x 20 mL).  The combined organic 
layers were washed with 10% NaHCO3 (30 mL), 1 M HCl (30 mL), and H2O (30 mL).  The 
resulting solution was dried over MgSO4 and concentrated under vacuum.  Final product was a 
black/yellow oil (0.20 g, 1.30 mmol, 97%).  1H NMR (CDCl3), δ 0.95 (t, 3H), 1.58 (sextet, 2H), 
2.47 (t, 2H), 5.91 (br d, 2 H), 6.63 (d, 1H), 6.73 (s, 1H), 6.80 (d, 1H). 
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 4.3.2 Partial Synthesis of Analogues 1 and 4 
4.3.2.1 2-(3,4-Dimethoxybenzylidene)succinic acid (9)33 
 
9 
To a stirring mixture of 3,4-dimethoxybenzaldehyde (5.01 g, 30.1 mmol) and diethyl 
succinate (10.5 g, 60.2 mmol) in ethanol (42 mL) was added 28% NaOEt solution in ethanol (12 
mL).  The reaction mixture was refluxed 20 h under N2(g).  2 M NaOH was added, and the 
resulting mixture refluxed a further 5 h.  The reaction mixture was then cooled and concentrated 
under vacuum.  H2O (42 mL) and conc. HCl (42 mL) was added, and extracted with ethyl acetate 
(84 mL + 3 x 42 mL).  Combined organic extracts were washed with H2O (100 mL) and dried 
over MgSO4.  Solution was concentrated under vacuum, and the resulting residue washed with 
ethyl acetate.  The final product, a pale orange powder, was vacuum filtered and rinsed with 
small amounts of ethyl acetate (4.95 g, 18.5 mmol, 61%). 1H NMR (MeOD), δ 3.54 (s, 2H), 3.84 
(s, 3H), 3.86 (s, 3H), 7.01 (s, 2H), 7.05 (s, 1H), 7.84 (s, 1H).  13C NMR (MeOD), δ 29.96, 56.55, 
56.76, 112.85, 113.94, 124.23, 126.14, 129.46, 143.10, 150.54, 151.56, 175.37, 176.31. 
4.3.2.2 Diethyl 2-(3,4-dimethoxybenzylidene)succinate (10)33 
 
10 
To a stirring mixture of 9 (4.95 g, 18.5 mmol) in ethanol (70 mL) was added concentrated 
H2SO4 (2.1 mL) and refluxed 42h.  The reaction mixture was cooled and concentrated under 
vacuum.  H2O (61 mL) was added to the residue, and extracted with ethyl acetate (92 mL + 2 x 
37 mL).  The combined organic extracts were washed with H2O (80 mL) and dried over MgSO4.  
The solution was concentrated under vacuum, and the resulting residue chromatographed over Si 
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 gel (4:1 petroleum ether: ethyl acetate) via flash column.  Final product was a yellow oil (5.67 g, 
17.6 mmol, 95%).  1H NMR (CDCl3), δ 1.24 (t, 3 H), 1.30 (t, 3H), 3.54 (s, 2H), 3.88 (s, 3H), 
3.90 (s, 3H), 4.14 (q, 2H), 4.23 (q, 2H), 6.82 (d, 1H), 6.97 (m, 2H), 7.84 (s, 1H).  13C NMR 
(CDCl3), δ 14.08, 14.18, 33.83, 55.74, 55.80, 60.83, 60.91, 111.01, 112.14, 122.51, 124.43, 
127.69, 141.56, 148.78, 149.69, 167.42, 171.25. 
4.3.3 Synthesis of Analogue 1 
4.3.3.1 2-(3,4-Dimethoxybenzylidene)-3-(ethoxycarbonyl)-4-phenylbut-3-enoic 
acid (11)33 
 
11 
To a stirring mixture of benzaldehyde (0.880 g, 8.30 mmol) and 10 (2.43 g, 7.54 mmol) 
in ethanol (31 mL) was added 28% NaOEt solution in ethanol (6.2 mL) and refluxed 5 h under 
N2(g).  Reaction mixture was cooled, and H2O (12 mL) and conc. HCl (3.0 mL) were added.  The 
resulting mixture was extracted with ethyl acetate (26 mL + 2 x 15 mL), and the combined 
organic extracts washed with H2O (25 mL) and dried over MgSO4.  The solution was 
concentrated under vacuum, and the resulting residue chromatographed over Si gel (2:1 
petroleum ether: ethyl acetate) via flash column, flushing column with methanol following 
collection of fractions.  Final product was an extremely viscous yellow oil (2.59 g, 7.16 mmol, 
95%).  1H NMR (MeOD), δ 1.13 (t, 3H), 3.73 (s, 3H), 3.84 (s, 3H), 4.15 (q, 2H), 6.75 (d, 1H), 
7.06 (m, 2H) 7.23 (s, 3H), 7.48 (d, 2H), 7.88 (s, 1H), 7.92 (s, 1H). 
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 4.3.3.2 Diethyl 2-benzylidene-3-(3,4-dimethoxybenzylidene)succinate (12)33 
 
12 
To a stirring mixture of 11 (3.28g, 9.06 mmol) in ethanol (35 mL) was added 
concentrated H2SO4 (0.50 mL), and the resulting solution refluxed 16 h.  The reaction mixture 
was cooled and concentrated under vacuum.  H2O (30 mL) was added to the residue, and 
extracted with ethyl acetate (45 mL + 2 x 18 mL).  The combined organic extracts were washed 
with H2O (40 mL) and dried over MgSO4.  The solution was concentrated under vacuum and the 
resulting residue chromatographed over Si gel (4:1 petroleum ether: ethyl acetate) via flash 
column.  Final product is a very pale yellow non-viscous liquid (1.75 g, 4.26 mmol, 47%).  1H 
NMR (CDCl3), δ 1.10 (t, 3H), 1.15 (t, 3H), 3.79 (s, 3H), 3.89 (s, 3H), 4.16 (m, 4H), 6.82 (d, 1H), 
7.11 (d, 2H), 7.30 (m, 3H), 7.49 (m, 2H), 7.87 (s, 1H), 7.94 (s, 1H).13C NMR (CDCl3), δ 14.26, 
14.33, 55.88, 56.05, 61.20, 61.37, 111.04, 112.03, 124.48, 124.84, 127.89, 128.01, 128.76, 
129.71, 129.84, 135.18, 142.56, 142.72, 148.89, 150.50, 167.16, 167.32. 
4.3.3.3 Diethyl 2-benzyl-3-(3,4-dimethoxybenzyl)succinate (13)34 
H3CO
H3CO
O
O
O
O
 
13 
To a stirring solution of 12 (1.75 g, 4.26 mmol) in ethanol (913 mL) was added Pd/C 
(21%).  The flask was evacuated and flushed with H2(g) several times once it had been stoppered 
and sealed tightly.  The mixture was stirred under H2(g) at atmospheric pressure at room 
temperature 68 h.  The reaction mixture was filtered through Celite and concentrated under 
vacuum.  Resulting product was a yellow oil (1.74 g, 4.26 mmol, 99%).  1H NMR (CDCl3), δ 
1.12 (m, 6H), 2.92 (m, 6H), 3.65 (s, 3H), 3.78 (s, 3H), 4.02 (m, 4H), 6.68 (m, 2H), 6.83 (d, 1H), 
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 7.14 (m, 5H).  13C NMR (CDCl3) δ 14.09, 14.14, 35.24, 35.64, 47.86, 48.14, 55.78, 55.96, 60.71, 
60.73, 111.18, 112.14, 121.24, 126.53, 128.43, 128.98, 129.12, 131.23, 138.73, 147.68, 148.83, 
173.50.  
4.3.3.4 2-Benzyl-3-(3,4-dimethoxybenzyl)butane-1,4-diol (14)35 
 
14 
A stirring mixture of LiAlH4 (0.17 g, 4.61 mmol) in THF (9 mL) under N2(g) was cooled 
to 0°C.  13 (0.87 g, 2.10 mmol) dissolved in THF (7 mL) was slowly added via syringe to the 
reaction vessel.  The reaction was warmed to room temperature and stirred for 2 h.  The reaction 
was then cooled to 0°C and quenched with H2O (0.17 mL), added dropwise very slowly, at a 
ratio of 1 mL H2O/1 g LAH.  Following 5 min of stirring, 15% w/v NaOH solution (0.17 mL) 
was added at a ratio of 1 mL/1 g LAH.  Reaction was then warmed to room temperature with 
continued stirring.  A further aliquot of H2O (0.51 mL) was added at a ratio of 3 mL/1 g LAH.  
The resulting mixture was filtered through Celite by vacuum filtration, and the residue rinsed 
with ethyl acetate.  The solution was concentrated under vacuum and the resulting residue 
chromatographed over Si gel (1:1 petroleum ether: ethyl acetate) via flash column (0.59 g, 1.65 
mmol, 78%).  1H NMR (CDCl3) δ 2.07 (m, 2H), 2.78 (m, 4H), 3.50 (m, 4H), 3.83 (s, 3H), 3.87 
(s, 3H), 6.66 (s, 1H), 6.72 (m, 1H), 6.78 (d, 1H), 7.16 (d, 1H), 7.22 (t, 2H), 7.28 (t, 2H).  13C 
NMR (CDCl3) δ 35.98, 36.38, 44.16, 44.21, 56.00, 56.11, 60.62, 60.72, 111.30, 112.22, 121.20, 
126.20, 128.58, 129.25, 133.30, 140.82, 147.47, 149.05. 
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 4.3.3.5 2-Benzyl-3-(3,4-dimethoxybenzyl)butane-1,4-diyl bis(4-
methylbenzenesulfonate) (15)19 
 
15 
A stirring solution of 14 (0.63 g, 1.9 mmol) in pyridine (2.5 mL) under N2(g) was cooled 
to 0°C for 20 min.  p-TsCl (1.19 g, 6.3 mmol) was added, and the mixture then stirred at 0°C for 
4 h.  The reaction was quenched with 2 M HCl (14 mL) and extracted with EtOAc (30 mL).  The 
resulting mixture was then vacuum filtered, isolating the filtrate.  It was then extracted a further 
two times with EtOAc (2 x 15 mL), and the combined organic layers dried with MgSO4.  The 
resulting solution was concentrated under vacuum, and the resulting residue chromatographed 
over Si gel (2:1 hexane: ethyl acetate) via flash column, isolating a white crystalline solid (0.49 
g, 0.76 mmol, 40%).  1H NMR (CDCl3) δ 2.09 (m, 2H), 2.47 (s, 6H), 2.51 (m, 2H), 2.69 (m, 2H), 
3.80 (s, 3H), 3.87 (s, 3H), 3.94 (m, 4H), 6.49 (d, 1H), 6.55 (s, 1H), 6.67 (d, 1H), 6.90 (m, 2H), 
7.17 (m, 3H), 7.33 (d, 4H), 7.72 (m, 4H).   13C NMR (CDCl3) δ 21.89, 33.94, 34.29, 40.18, 
40.29, 56.01, 56.10, 69.68, 69.76, 111.26, 112.06, 121.13, 126.59, 128.14, 128.71, 129.08, 
130.15, 131.36, 132.77, 132.79, 138.88, 145.18, 147.76, 149.21. 
4.3.3.6 4-(2,3-Dimethyl-4-phenylbutyl)-1,2-dimethoxybenzene (16)19, 35 
 
16 
A stirring mixture of LiAlH4 (0.22 g, 5.8 mmol) in THF (16 mL) under N2(g) was cooled 
to 0°C.  15 (0.74 g, 1.2 mmol) dissolved in THF (8 mL) was slowly added via syringe to the 
reaction vessel.  The reaction was warmed to room temperature and stirred for 6 h.  The reaction 
was then cooled to 0°C and quenched with H2O (0.2 mL), added dropwise very slowly, at a ratio 
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 of 1 mL H2O/1 g LAH.  Following 5 min of stirring, 15% w/v NaOH solution (0.2 mL) was 
added at a ratio of 1 mL/1 g LAH.  The reaction was then warmed to room temperature with 
continued stirring.  A further aliquot of H2O (0.6 mL) was added at a ratio of 3 mL/1 g LAH.  
The resulting mixture was filtered through Celite by vacuum filtration, and the residue was 
rinsed with ethyl acetate.  The resulting solution was concentrated under vacuum and the residue 
chromatographed over Si gel (95:5 hexane: ethyl acetate) via flash column.  Final product was a 
yellow oil (0.34 g, 1.1 mmol, 92%)  1H NMR (CDCl3) δ 0.87 (m, 6H), 1.82 (m, 2H), 2.46 (2 x 
dd, 2H), 2.65 (2 x dd, 2H), 3.85 (s, 3H), 3.89 (s, 3H), 6.60 (s, 1H), 6.67 (m, 1H), 6.80 (d, 1H), 
7.13 (d, 2H), 7.21 (m, 2H), 7.30 (t, 1H).  13C NMR (CDCl3) δ 14.08, 14.12, 37.94, 38.03, 41.18, 
41.61, 55.94, 56.09, 111.10, 112.17, 121.08, 138.31, 129.22, 129.31, 134.40, 141.86, 147.20, 
148.86. 
4.3.3.7 4-(2,3-Dimethyl-4-phenylbutyl)benzene-1,2-diol (1)18, 32 
 
1 
A stirring mixture of 16 (0.30 g, 1.0 mmol) in anhydrous DCM (10 mL) under N2(g) was 
cooled to -78°C.  BBr3 (1 M in DCM, 5 mL) was added to the solution via syringe and the 
resulting mixture was stirred for 2 h.  The solution was warmed to room temperature, quenched 
with H2O (10 mL), and extracted with EtOAc (20 mL + 2 x 10 mL).  The combined organic 
layers were washed with 10% NaHCO3 (15 mL), 1 M HCl (15 mL), and H2O (15 mL).  The final 
solution was dried over MgSO4 and concentrated under vacuum.  Final product was a dark 
yellow/black oil (0.25 g, 0.92 mmol, 92%).  1H NMR (CDCl3) δ 0.86 (m, 6H), 1.80 (m, 2H), 
2.35 (dd, 1H), 2.46 (dd, 1H), 2.56 (dd, 1H), 2.66 (dd, 1H), 5.09 (br s, 2H), 6.56 (d, 1H), 6.60 (s, 
1H), 6.78 (d, 1H), 7.14 (d, 2H), 7.22 (m, 1H), 7.29 (m, 2H).  13C NMR 14.14, 16.43, 38.20, 
39.48, 40.83, 41.60, 115.39, 116.19, 121.70, 125.79, 128.33, 129.30, 135.04, 141.53, 141.94, 
143.42.  MS-ESI(-) m/z 269.13. 
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 4.3.4 Partial Synthesis of Analogues 2 and 3 
4.3.4.1 4-Benzyloxy-3-methoxybenzaldehyde (17)31 
 
17 
To a stirring solution of vanillin (10.0 g, 65.8 mmol) in EtOH (258 mL) under N2(g) was 
added K2CO3 (13.6 g, 62.2 mmol) and BnBr (7.81 mL, 98.7 mmol).  The mixture was stirred 
overnight, approximately 22 h.  The reaction mixture was then filtered through Celite, and the 
filtrate concentrated under vacuum to approximately 25% the original volume.  The resulting 
solution was diluted with EtOAc, and was washed with 1 M H3PO4, saturated NaCl solution, and 
dried over MgSO4.  The final solution was concentrated under vacuum, and the resulting residue 
chromatographed over Si gel (5:1 hexane: ethyl acetate) via flash column.  The final product was 
an off-white solid (11.6 g, 48.0 mmol, 73%).  1H NMR (CDCl3) δ 3.88 (s, 3H), 5.18 (s, 2H), 6.95 
(d, 1H), 7.29 (m, 1H), 7.37 (m, 3H), 7.33 (m, 3H), 9.80 (s, 1H).  13C NMR (CDCl3) δ 56.23, 
71.03, 109.52, 112.56, 126.77, 127.38, 128.39, 128.90, 130.47, 136.19, 150.25, 153.77, 191.08. 
4.3.4.2 2-(4-(Benzyloxy)-3-methoxybenzylidene)succinic acid (18)33 
 
18 
To a stirring mixture of 17 (9.53 g, 39.3 mmol) and diethyl succinate (20.6 mL, 123 
mmol) in ethanol (55 mL) was added 28% NaOEt solution in ethanol (15 mL), and refluxed 5 h 
under N2(g).  2 M NaOH (110 mL) was added and refluxed a further 15 h.  The reaction mixture 
was cooled and concentrated under vacuum.  H2O (55 mL) and conc. HCl (55 mL) were added, 
and extracted with ethyl acetate (110 mL + 2 x 55 mL).  The combined organic extracts were 
washed with H2O and dried over MgSO4.  The resulting solution was concentrated under 
vacuum, and the resulting residue washed with ethyl acetate.  The final product was vacuum 
filtered and rinsed with a small amount of ethyl acetate to give a pale yellow powder (11.89 g, 
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 34.7 mmol, 88%).  1H NMR (MeOD) δ 3.56 (s, 2H), 3.88 (s, 3H), 5.13 (s, 2H), 6.98 (d, 1H), 7.06 
(d, 1H), 7.10 (s, 1H), 7.33 (d, 2H), 7.39 (t, 1H), 7.47 (d, 2H), 7.85 (s, 1H).  13C NMR (MeOD) δ 
28.43, 55.07, 70.55, 112.75, 113.67, 122.50, 124.78, 127.31, 127.60, 128.11, 128.41, 137.01, 
141.46, 149.04, 149.58, 169.70, 174.75. 
4.3.4.3 Diethyl 2-(4-(benzyloxy)-3-methoxybenzylidene)succinate (19)33 and 
diethyl-2-(4-hydroxy-3-methoxybenzylidene)succinate (20) 
 
    19     20 
To a stirring mixture of 18 (11.89 g, 34.7 mmol) in ethanol (132 mL) was added 
concentrated H2SO4 (4.0 mL) and refluxed 16 h.  The reaction mixture was then cooled and 
concentrated under vacuum.  H2O (115 mL) was added to the residue, and extracted with ethyl 
acetate (174 mL + 2 x 69 mL).  The combined organic extracts were washed with H2O and dried 
over MgSO4.  The resulting solution was concentrated under vacuum, and the resulting residue 
chromatographed over Si gel (4:1 petroleum ether: ethyl acetate) via flash column. The desired 
product 19 was a yellow oil (5.03 g, 12.6 mmol, 36%).    1H NMR (CDCl3) δ 1.27 (t, 3H), 1.34 
(t, 3H), 3.57 (s, 2H), 3.89 (s, 3H), 4.19 (q, 2H), 4.28 (q, 2H), 5.19 (s, 2H), 6.89 (m, 2H), 6.97 (s, 
1H), 7.27 (d, 2H), 7.32 (t, 1H), 7.41 (d, 2H), 7.82 (s, 1H).  13C NMR (CDCl3) δ 14.22, 29.20, 
33.93, 55.97, 60.68, 60.97, 70.88, 112.75, 113.52, 122.40, 124.61, 127.23, 127.99, 128.21, 
128.63, 136.74, 141.66, 148.88, 149.44, 167.58, 171.40.  Also isolated was the de-benzylated 
entity 20 (3.87 g, 12.5 mmol, 36%).  1H NMR (CDCl3) δ 1.26 (t, 3H), 1.32 (t, 3H), 3.57 (s, 2H), 
3.88 (s, 3H), 4.18 (q, 2H), 4.27 (q, 2H), 6.93 (d, 3 H), 7.83 (s, 1H). 
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 4.3.4.4 Diethyl 2-(4-(benzyloxy)-3-methoxybenzylidene)succinate (19) 
 
19 
To a stirring mixture of 20 (4.6 g, 14.8 mmol) in EtOH (58 mL) under N2(g) was added 
K2CO3 (3.07 g, 22.2 mmol) and BnBr (3.52 mL, 29.6 mmol).  The mixture was stirred overnight, 
approximately 22 h.  The reaction mixture was then filtered through Celite, and the filtrate 
concentrated under vacuum to approximately 25% the original volume.  The resulting solution 
was diluted with EtOAc, and was washed with 1 M H3PO4, saturated NaCl solution, and dried 
over MgSO4.  The final solution was concentrated under vacuum, and the resulting residue 
chromatographed over Si gel (6:1 hexane: ethyl acetate) via flash column.  The final product was 
a yellow oil (5.07 g, 12.7 mmol, 86%).  NMR as per 19 (4.3.4.3) above.  
4.3.5 Partial Synthesis of Analogue 2 
4.3.5.1 2-(4-(Benzyloxy)-3-methoxybenzylidene)-3-(ethoxycarbonyl)-4-
phenylbut-3-enoic acid (21)33 
 
21 
To a stirring mixture of benzaldehyde (1.50 mL, 14.8 mmol) and 19 (5.39 g, 13.5 mmol)  
in ethanol (56 mL) was added 28% NaOEt solution in ethanol (8.7 mL), and refluxed 5 h under 
N2(g).  The reaction mixture was cooled, and H2O (18.9 mL) and conc. HCl (18.9 mL) was added, 
and extracted with ethyl acetate (37.8 mL + 2 x 18.9 mL).  The combined organic extracts were 
washed with H2O and dried over MgSO4.  The resulting solution was concentrated under 
vacuum, and the resulting residue chromatographed over Si gel (2:1 petroleum ether: ethyl 
acetate) via flash column, flushing column with methanol following collection of fractions (6.58 
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 g, 14.4 mmol, 97%).  1H NMR (MeOD) δ 1.11 (t, 3H), 3.63 (s, 3H), 4.13 (q, 2H), 4.93 (s, 2H), 
6.79 (d, 1H), 6.98 (d, 1H), 7.13 (s, 1H), 7.21 (m, 2H) 7.26 (t, 3H), 7.33 (m, 3H), 7.48 (m, 2H), 
7.86 (s, 1H), 7.92 (s, 1H).  13C NMR (MeOD) δ 13.23, 48.61, 54.93, 61.04, 70.30, 112.25, 
113.20, 123.99, 125.54, 127.34, 127.66, 128.10, 128.15, 128.20, 128.32. 128.61, 129.42, 129.48, 
134.83, 136.77, 142.03, 142.06, 149.27, 149.59, 167.38, 169.24.   
4.3.5.2 Diethyl 2-benzylidene-3-(4-(benzyloxy)-3-
methoxybenzylidene)succinate (22)33 and diethyl 2-benzylidene-3-(4-hydroxy-
3-methoxybenzylidene)succinate (23) 
 
  22           23 
To a stirring mixture of 21 (3.76 g, 8.20 mmol) in ethanol (31.1 mL) was added 
concentrated H2SO4 (0.46 mL) and refluxed 16 h.  The reaction mixture was cooled and 
concentrated under vacuum.  H2O (27 mL) was added to the residue and extracted with ethyl 
acetate (41 mL + 2 x 16 mL).  The combined organic extracts were washed with H2O and dried 
over MgSO4.  The resulting solution was concentrated under vacuum and the final residue 
chromatographed over Si gel (4:1 petroleum ether: ethyl acetate) via flash column to give the 
final product, a colourless oil (0.34 g, 0.71 mmol, 8.6%).  1H NMR (CDCl3) δ 1.11 (m, 6H), 3.79 
(s, 3H), 4.17 (m, 4H), 5.15 (s, 2H), 6.81 (d, 1H), 7.03 (d, 1H), 7.14 (s, 1H), 7.28 (m, 4H), 7.36 (t, 
2H), 7.41 (d, 2H), 7.48 (m, 2H), 7.86 (s, 1H), 7.94 (s, 1H).  13C NMR (CDCl3) δ 14.08, 14.13, 
55.77, 61.02, 61.18,  70.71, 112.34, 113.22, 124.08, 124.84, 127.22, 127.75, 127.99, 128.20, 
128.56, 128.61, 129.53, 129.62, 135.03, 136.62, 142.42, 142.56, 149.26, 149.44, 166.94, 167.10.  
Also isolated was 23, a colourless oil (0.37 g, 0.94 mmol, 11%).  1H NMR (CDCl3) δ 1.08 (t, 
3H), 1.11 (t, 3H), 3.78 (s, 3H), 4.14 (m, 4H), 6.84 (d, 1H), 7.04 (d, 1H), 7.09 (s, 1H), 7.28 (m, 
3H), 7.47 (m, 2H), 7.83 (s, 1H), 7.91 (s, 1H). 
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 4.3.5.3 1-Ethyl 4-methyl 2-benzylidene-3-(4-(benzyloxy)-3-
methoxybenzylidene)succinate (24)36  
 
24 
To stirring DMSO (18.6 mL) was added powdered KOH (1.04 g, 18.6 mmol), and resulting 
mixture stirred for 5 min.   21 (4.27 g, 9.30 mmol) was then added, along with CH3I (18.6 mmol, 
1.16 mL), and the final reaction mixture was stirred for 1 h.  H2O was added to the mixture (186 
mL), and was then extracted with DCM (3 x 186 mL).  The combined DCM extracts were 
washed with H2O (5 x 93 mL), dried over MgSO4, and concentrated under vacuum.  The 
resulting residue was chromatographed over Si gel (4:1 petroleum ether: ethyl acetate) via flash 
column to give the final product, a yellow oil (2.52 g, 5.33 mmol, 57%).  1H NMR (CDCl3) δ 
1.13 (t, 3H), 3.69 (s, 3H), 3.78 (s, 3H), 4.18 (q, 2H), 5.16 (s, 2H), 6.80 (d, 1H), 7.02 (d, 1H), 7.12 
(d, 1H), 7.28 (m, 4H), 7.28 (m, 2H), 7.32 (m, 2H), 7.46 (m, 2H), 7.85 (s, 1H), 7.93 (s, 1H). 
4.3.5.4 Diethyl 2-benzyl-3-(4-hydroxy-3-methoxybenzyl)succinate (25)34 
 
25 
To a stirring solution of 22 and 23 (0.77 g and 0.36 g, 2.50 mmol total) in ethanol (537 
mL) was added Pd/C (21%) and 3 drops of TFA.  The flask was stoppered and sealed tightly, and 
evacuated and flushed with H2(g) several times.  The mixture was stirred under H2(g) at room 
temperature 68 h.  The resulting reaction mixture was filtered through Celite and concentrated 
under vacuum.  Final product was a dark, black/purple oil (0.99 g, 2.47 mmol, 99%)  1H NMR 
(CDCl3) δ 1.14 (m, 6H), 2.84 (m, 4H), 2.94 (m, 2H), 3.75 (s, 3H), 3.99 (m, 4H)6.53 (d, 1H), 6.61 
(s, 1H), 6.66 (d, 1H), 7.07(d, 2H), 7.16 (d, 2H), 7.22 (t, 1H).  13C NMR (MeOD) δ 14.54, 14.58, 
33 
 
 36.65, 37.03, 50.18, 52.9, 56.45, 61.85, 61.88, 113.76, 116.20, 122.88, 127.71, 129.55, 129.59, 
131.36, 140.14, 146.48, 149.00, 175.34, 175.47. 
4.3.5.5 1-Ethyl 4-methyl 2-benzyl-3-(4-hydroxy-3-methoxybenzyl)succinate 
(26)34 
 
26 
To a stirring solution of 24 (2.03 g, 4.30 mmol) in ethanol (950 mL) was added Pd/C 
(21%) and 3 drops of TFA.  The flask was stoppered and sealed tightly, and evacuated and 
flushed with H2(g) several times.  The mixture was stirred under H2(g) at room temperature 68 h.  
The resulting reaction mixture was filtered through Celite and concentrated under vacuum.  Final 
product was a dark, black/purple oil (1.65 g, 4.27 mmol, 99%).  1H NMR (CDCl3) δ 1.26 (t, 3H), 
3.00 (m, 6H), 3.64 (s, 3H), 3.74 (q, 2H), 3.86 (s, 3H), 6.55 (s, 1H), 6.63 (m, 1H), 6.81 (d, 1H), 
7.10 (m, 2H), 7.21 (m, 2H), 7.29 (m, 1H). 
4.3.5.6 2-Benzyl-3-(4-hydroxy-3-methoxybenzyl)butane-1,4-diol (27)35 
 
27 
A stirring mixture of LiAlH4 (0.29 g, 7.6 mmol) in THF (16 mL) under N2(g) was cooled 
to 0°C.  25 and 26 (1.39 g, 3.63 mmol) dissolved in THF (6 mL) was slowly added to the flask 
via syringe.  The reaction was then allowed to warm to room temperature, and was stirred 2 h.  
The reaction was then cooled to 0°C, and quenched with H2O (0.3 mL), added dropwise very 
slowly, at a ratio of 1 mL H2O/1 g LAH.  Following 5 mins. of stirring, 15% w/v NaOH solution 
(0.3 mL) was added  at a ratio of 1 mL/1 g LAH.  The reaction was warmed to room temperature 
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 with continued stirring.  A further aliquot of H2O (0.9 mL) was added at a ratio of 3 mL/1 g 
LAH, and the resulting mixture was filtered through Celite by vacuum filtration, rinsing the 
residue with ethyl acetate.  The resulting solution was concentrated under vacuum and 
chromatographed over Si gel (3:1 ethyl acetate: petroleum ether) via flash column, flushing 
column with MeOH, isolating the final product as a colourless oil (0.49 g, 1.5 mmol, 41%).  1H 
NMR (MeOD) δ 1.91 (m, 2 H), 2.59 (m, 2H), 2.68 (m, 2H), 3.34 (s, 3H), 3.56 (m, 4H), 6.55 (d, 
1H), 6.63 (s, 1H), 6.68 (d, 1H), 7.13 (m, 5H).  13C NMR (MeOD) δ 35.98, 36.37, 44.38, 44.47, 
50.00, 56.36, 61.95, 61.99, 113.56, 116.00, 122.77, 126.89, 129.34, 130.29, 133.90, 142.55, 
145.61, 148.90. 
4.3.5.7 2-Benzyl-3-(3-methoxy-4-(tosyloxy)benzyl)butane-1,4-diyl bis(4-
methylbenzenesulfonate) (28)37 
 
28 
A stirring solution of 27 (0.49 g, 1.5mmol) in pyridine (1.8 mL) under N2(g) was cooled to 
0°C for 20 min.  p-TsCl (7.56 mmol) was added, and the mixture then stirred at 0°C for 8 h.  The 
reaction was quenched with 2 M HCl (11 mL) and extracted with EtOAc, and the combined 
organic layers dried with MgSO4.  The resulting solution was concentrated under vacuum, and 
the resulting residue washed with DCM isolating a white solid (0.43 g, 0.55 mmol, 37%).  1H 
NMR (CDCl3) δ 2.08 (m, 2H), 2.46 (s, 3H), 2.47 (s, 6H), 2.52 (m, 2H), 2.71 (m, 2H), 3.48 (s, 
3H), 3.90 (m, 4 H), 6.40 (d, 1H), 6.54 (s, 1H), 6.87 (m, 2H), 6.96 (d, 1H), 7.17 (d, 3H),   7.33 (m, 
6H), 7.72 (m, 6H).  13C NMR (CDCl3) δ 34.24, 40.17, 40.29, 55.72, 69.50, 69.63, 113.40, 
121.04, 124.07, 126.70, 128.08, 128.78, 128.82, 129.04, 129.56, 130.21, 130.25, 132.60, 133.41, 
137.11, 138.68, 139.23, 145.24, 145.32, 145.46, 151.95. 
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 4.3.5.8 4-(2,3-Dimethyl-4-phenylbutyl)-2-methoxyphenyl 4-
methylbenzenesulfonate (29) 19, 35 
 
29 
A stirring mixture of LiAlH4 (14.2 mg, 0.37 mmol) in THF (1.0 mL) under N2(g) was 
cooled to 0°C.  28 (53.7 mg, 0.0689 mmol) dissolved in THF (0.5 mL) was slowly added via 
syringe to the reaction vessel.  The reaction was warmed to room temperature, and then refluxed 
for 6 h.  The reaction was then cooled to room temperature, and then to 0°C and quenched with 
H2O added dropwise very slowly at a ratio of 1 mL H2O/1 g LAH.  Following 5 min of stirring, 
15% w/v NaOH solution was added at a ratio of 1 mL/1 g LAH.  The reaction was then warmed 
to room temperature with continued stirring.  A further aliquot of H2O was added at a ratio of 3 
mL/1 g LAH.  The resulting mixture was filtered through Celite by vacuum filtration, and the 
residue was rinsed with ethyl acetate.  The resulting solution was concentrated under vacuum 
and the residue chromatographed over Si gel (8:1 petroleum ether: ethyl acetate) via PTLC.  
Final product was a yellow oil (21.8 mg, 0.0497 mmol, 72%)  1H NMR (MeOD) δ 0.80 (m, 6H), 
1.71 (m, 2H), 2.38 (s, 3H) 2.41 (m, 2H), 2.53 (m, 2H), 3.34 (s, 3H), 6.52 (s, 1H), 6.58 (d, 1H), 
6.96 (d, 1H), 7.00 (d, 2H), 7.10 (d, 1H), 7.17 (d, 2H), 7.29 (d, 2H), 7.61 (d, 2H).  13C NMR 
(MeOD) δ 14.29, 16.63, 21.74, 38.82, 42.28, 42.50, 55.99, 114.39, 122.08, 124.55, 126.86, 
129.33, 129.94, 130.12, 130.55, 134.42, 137.77, 142.90, 143.75, 146.86, 152.83. 
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 4.3.6 Partial Synthesis of Analogue 3 
4.3.6.1 2-(4-(Benzyloxy)-3-methoxybenzylidene)-4-(4-(benzyloxy)-3-
methoxyphenyl)-3-(ethoxycarbonyl)but-3-enoic acid (30)33 
 
30 
To a stirring mixture of 17 (1.75 g, 7.24 mmol) and 19 (2.62 g, 6.58 mmol) in ethanol 
(27.3 mL) was added 28% NaOEt solution in ethanol (4.9 mL) and refluxed 5 h under N2(g).  The 
reaction mixture was then cooled, and H2O and conc. HCl (2.6 mL) were added.  The resulting 
mixture was extracted with ethyl acetate, and the combined organic extracts washed with H2O 
and dried over MgSO4.  The resulting solution was concentrated under vacuum, and the resulting 
residue washed with ethyl acetate.  The final product, a pale yellow powder, was vacuum-filtered 
and rinsed with small amounts of ethyl acetate (1.62 g, 2.72 mmol, 41%).  1H NMR (d6-DMSO) 
δ 1.06 (t, 3H), 3.64 (m, 6H), 4.09 (m, 2H), 5.06 (br s, 4H), 7.01 (m, 2H), 7.11 (m, 2H), 7.18 (s, 
1H), 7.23 (s, 1H), 7.38 (br m, 10 H), 7.76 (s, 2H).  13C NMR (d6-DMSO) δ 13.94, 55.27, 60.78, 
70.06, 113.11, 123.56, 123.76, 125.35, 125.62, 127.45, 127.57, 127.83, 127.87, 127.94, 128.42, 
136.69, 140.78, 148.67, 149.17, 149.31, 166.44, 167.79. 
4.3.6.2 1-Ethyl 4-methyl 2,3-bis(4-(benzyloxy)-3-
methoxybenzylidene)succinate (31)36 
 
31 
To DMSO (0.56 mL) was added powdered KOH (63.3 mg, 1.13 mmol), and stirred for 5 
min.  30 (168 mg, 0.282 mmol) was then added, along with CH3I (0.035 mL, 0.564 mmol), and 
stirred for another 1 h.  To this solution was added H2O (5.6 mL), and the resulting mixture 
extracted with three aliquots of DCM (3 x 5.6 mL).  The combined organic extracts were then 
washed with 5 aliquots of H2O (5 x 2.8 mL), and dried over MgSO4.  The resulting solution was 
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 concentrated to give a yellow oil (165 mg, 0.270 mmol, 96%).  1H NMR (CDCl3) δ 1.13 (t, 3H), 
3.70 (s, 3H), 3.77 (s, 6H), 4.18 (q, 2H), 5.14 (s, 4H), 6.81 (d, 2H), 7.05 (d, 2H), 7.19 (m, 2 H), 
7.30 (m, 2H), 7.35 (t, 4H), 7.41 (m, 4H), 7.90 (s, 2H).  13C NMR (CDCl3) δ 14.39, 52.53, 55.94, 
61.24, 70.90, 112.54, 113.34, 124.53, 124.93, 125.11, 127.41, 128.20, 128.26, 128.42, 128.82, 
128.95, 136.79, 142.24, 124.44, 149.41, 149.74, 167.34, 168.03. 
4.3.7 Partial Synthesis of Analogue 4 
4.3.7.1 3,4-Bis(benzyloxy)benzaldehyde (32)31 
 
32 
To a stirring solution of 3,4-dihydroxybenzaldehyde (5.03 g, 36.4 mmol) in ethanol (143 
mL) under N2(g) was added K2CO3 (15.1 g, 109.2 mmol) and BnBr (8.65 mL, 72.8 mmol).  The 
reaction was stirred over night, and the resulting mixture filtered through Celite.  The filtrate was 
diluted with EtOAc, and washed with 1M H3PO4 and saturated NaCl solution.  The organic 
extracts were dried over MgSO4, and concentrated under vacuum.  The crude product was 
recrystallized with MeOH, and the final product, a pale yellow solid, was collected via vacuum 
filtration (1.32 g, 4.15 mmol, 11%).  1H NMR (CDCl3) δ 5.23 (s, 2H), 5.27 (s, 2H), 7.03 (d, 1H), 
7.38-7.50 (br m, 12 H), 9.82 (s, 1H).  13C NMR (CDCl3) δ 71.06, 71.20, 112.61, 113.31, 126.90, 
126.90, 127.53, 128.23, 128.34, 128.80, 128.88, 130.53, 136.45, 136.76, 149.42, 154.48, 191.04.     
4.3.7.2 4-(3,4-Bis(benzyloxy)phenyl)-2-(3,4-dimethoxybenzylidene)-3-
(ethoxycarbonyl)but-3-enoic acid (33)33 
 
33 
To a stirring mixture of 10 (1.19 g, 3.70 mmol) and 32 (1.30 g, 4.07 mmol) in ethanol 
(15.4 mL) was added 28% NaOEt solution in ethanol (4.3 mL), and the resulting solution 
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 refluxed under N2(g).  The reaction mixture was cooled, and conc. HCl (5.7 mL) and H2O (5.7 
mL) was added and extracted with EtOAc.  The combined organic extracts were dried over 
MgSO4, and the resulting solution concentrated under vacuum.  The final residue was 
chromatographed over Si gel (2:1 petroleum ether: ethyl acetate), with the column flushed with 
methanol to give a yellow solid (1.16 g, 1.96 mmol, 53%).  1H NMR (d6-DMSO) δ 1.05 (t, 3H), 
3.72 (s, 3H), 3.75 (s, 3H), 4.11 (q, 2H), 5.10 (m, 2H), 5.18 (s, 2H), 6.91 (d, 1H), 7.02 (d, 1H), 
7.08 (d, 1H), 7.10 (s, 1H), 7.13 (d, 1H), 7.28 (d, 1H), 7.32 (t, 3H), 7.36 (m, 5H), 7.40 (d, 2H), 
7.40 (d, 2H).  13C NMR (d6-DMSO) δ 14.09, 48.60, 55.13, 55.46, 60.35, 69.76, 69.85, 111.55, 
113.65, 127.54, 127.80, 127.86, 128.35, 128.42, 136.79, 136.86, 147.55, 148.26. 
4.3.7.3 1-Ethyl 4-methyl 2-(3,4-bis(benzyloxy)benzylidene)-3-(3,4-
dimethoxybenzylidene)succinate (34)36 
 
34 
To DMSO (3.4 mL) was added powdered KOH (0.38 g, 6.79 mmol), and stirred for 5 
min.  33 (1.01 g, 1.70 mmol) was then added, along with CH3I (0.21 mL, 3.40 mmol), and stirred 
for another 1 h.  To this solution was added H2O (34 mL), and the resulting mixture extracted 
with three aliquots of DCM (3 x 34 mL).  The combined organic extracts were then washed with 
5 aliquots of H2O (5 x 17 mL), and dried over MgSO4.  The resulting solution was concentrated, 
and the residue chromatographed over Si gel (5:2 hexane: ethyl acetate) via flash column.  Final 
product was a yellow oil (0.58 g, 0.95 mmol, 56%).  1H NMR (CDCl3) δ 1.13 (t, 3H), 3.68 (s, 
3H), 3.72 (s, 3H), 3.89 (s, 3H),  4.15 (q, 2H), 5.09 (m, 2H), 5.18 (s, 2H), 6.80 (d, 1H), 6.86 (d, 
1H), 7.07 (m, 3H),  7.20 (s, 1 H), 7.29 (m, 4H), 7.37 (m, 4H), 7.42 (m, 2H), 7.83 (s, 2H).  13C 
NMR (CDCl3) δ 14.41, 52.51, 55.84, 56.05, 61.24, 71.01, 71.03, 110.98, 111.97, 114.11, 115.28, 
124.69, 124.71, 125.06, 125.25, 127.30, 127.33, 127.92, 127.94, 128.12, 128.28, 128.64, 128.75, 
136.95, 137.03, 142.26, 142.62, 148.60, 148.86, 150.48, 150.57, 167.30, 167.92. 
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 4.3.7.4 1-Ethyl 4-methyl 2-(3,4-dihydroxybenzyl)-3-(3,4-
dimethoxybenzyl)succinate (35)34 
 
35 
To a stirring solution of 34 (0.56 g, 0.91 mmol) in ethanol (196 mL) was added Pd/C 
(21%) and 3 drops of TFA.  The flask was stoppered and sealed tightly, and evacuated and 
flushed with H2(g) several times.  The mixture was stirred under H2(g) at room temperature 68 h.  
The resulting reaction mixture was filtered through Celite and concentrated under vacuum.  Final 
product was a purple/black oil (0.39 g, 0.90 mmol, 99%).  1H NMR (CDCl3) δ 1.20 (t, 3H), 2.85 
(m, 4H), 2.99 (m, 2H), 3.63 (s, 3H), 3.85 (s, 6H), 4.10 (q, 2H), 6.49 (m, 2H), 6.56 (s, 1H), 6.76 
(s, 1H), 7.41 (m, 2H).  13C NMR (CDCl3) δ 14.23, 35.13, 35.43, 47.93, 47.98, 55.99, 56.06, 
58.68, 61.02, 109.60, 111.33, 112.21, 112.58, 115.41, 116.28, 121.47, 128.92, 131.04, 144.00, 
147.67, 148.82, 174.04, 174.40.    
4.3.8 Synthesis of Anhydrosecoisolariciresinol (ASECO) 
 
ASECO 
 
 To secoisolariciresinol (SECO) (254 mg, 0.702 mmol) dissolved in methanol (30 mL) 
was added 15 drops of concentrated HCl, and the reaction mixture was refluxed for 20 h.  The 
reaction was quenched with H2O (30 mL) and extracted with ethyl acetate (3 x 40 mL).  The 
organic layer was washed with sodium bicarbonate (0.6 M, 80 mL), H2O (80 mL) and dried over 
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 MgSO4.  The organic layer was concentrated under vacuum and the residue chromatographed 
over Si gel (9:1 dichloromethane: ethyl acetate) via flash column.  Resulting product was an off-
white powder (0.267 mmol, 91.9 mg, 38%).  1H NMR (CDCl3) δ 2.19 (m, 2 H), 2.56 (m, 4 H), 
3.56 (dd, 2 H), 3.88 (s, 6 H), 3.95 (dd, 2 H), 6.51 (s, 2 H), 6.59 (d, 2 H), 6.81 (d, 2H), 7.27 (s, 2 
H). 
4.3.9 Oxidation Experiments 
4.3.9.1 Incubation of 1 in Rat Liver Microsomes11 
0.5 mM 1 and 5.0 mM GSH were incubated in 50 mM Na2HPO4 at pH 7.4 with 0.5 
mg/mL CYP (rat liver microsomes) and 5.0 mM MgCl2 at 37ºC for 60 min at a final reaction 
volume of 500 µL.  Reaction was initiated by addition of 1 mM NADPH and terminated by 
addition of 50 μL ice cold 2 mM salicylamide in acetonitrile.  Reaction was centrifuged at 
14,000 rpm for 10 min, and supernatant was analyzed by HPLC and by UPLC-MS. 
Simultaneously, 0.5 mM 1 was incubated in 50 mM Na2HPO4 at pH 7.4, 0.5 mM 1 and 
5.0 mM GSH were incubated in 50 mM Na2HPO4 at pH 7.4, 0.5 mM 1 was incubated in 50 mM 
Na2HPO4 at pH 7.4 with 0.5 mg/mL CYP, 5.0 mM MgCl2, and 1 mM NADPH, 0.5 mM 1 and 
5.0 mM GSH were incubated in 50 mM Na2HPO4 at pH 7.4 with 0.5 mg/mL heat inactivated 
microsomes, 5.0 mM MgCl2, and 1 mM NADPH, and finally, 0.5 mM 1 and 5.0 mM GSH were 
incubated in 50 mM Na2HPO4 at pH 7.4 with 0.5 mg/mL CYP, and 5.0 mM MgCl2.  All control 
reactions were performed at a final volume of 500 µL for 60 min and included the addition of 
salicylamide solution as per the active incubation.  Each reaction was performed in triplicate. 
4.3.9.2 Mushroom Tyrosinase Oxidation 111 
1.0 mM 1, 0.23 U/μL mushroom tyrosinase, and 5.0 mM glutathione in Na2HPO4 buffer 
(pH 6.0) at a total volume of 500 µL were vortexed for 60 min at 22ºC. Reaction was quenched 
with perchloric acid, and resulting mixture centrifuged 14,000 rpm for 10 min.  Supernatant was 
analyzed by HPLC and UPLC-MS. 
Control reactions were also performed in the absence of GSH, in the absence of 
mushroom tyrosinase, and with the addition of GSH after the 60 min vortex.  Each reaction was 
performed in triplicate. 
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 4.3.9.3 Ag2O Oxidation 111 
1.0 mM 1 and 4.1 mM Ag2O in acetonitrile at a total volume of 500 µL were incubated at 
37°C for 2 h.  Resulting mixture was centrifuged at 14,000 rpm for 10 min, and the resulting 
supernatant was added to GSH, with a final concentration of 5.0 mM (pH 7.4).  This solution 
was analyzed via HPLC. 
One control reaction was also performed in the absence of GSH.  Each reaction was 
performed in duplicate. 
4.3.9.4 Horseradish Peroxidase Oxidation 138 
0.5 mM 1, 100 µg/mL horseradish peroxidase, and 0.5 mM H2O2 was incubated with 1 
mM GSH in 50 mM Na2HPO4 buffer (pH=7.4) at 37°C.  One set of data was collected after 60 
min and one set after 120 min.  Reactions were quenched with 25 µL perchloric acid, and 
resulting mixture centrifuged at 14,000 rpm for 10 min.  Supernatant was analyzed via HPLC.  
Each of the two experiments with varying lengths was performed in triplicate. 
4.3.9.5 Incubation of ASECO in Rat Liver Microsomes11 
 0.5 mM ASECO and 5.0 mM GSH were incubated in 50 mM Na2HPO4 at pH 7.4 with 
0.5 mg/mL CYP (rat liver microsomes) and 5.0 mM MgCl2 to a volume of 500 µL at 37ºC for 60 
min.  Reaction was initiated by addition of 1 mM NADPH and terminated by addition of 50 μL 
ice cold 2 mM salicylamide in acetonitrile.  Reaction was centrifuged at 14,000 rpm for 10 min, 
and supernatant was analyzed by HPLC and UPLC-MS. 
Simultaneously, the following control reactions were also performed: 0.5 mM ASECO 
was incubated in 50 mM Na2HPO4 at pH 7.4 with 0.5 mg/mL CYP, 5.0 mM MgCl2 and 
NADPH; 0.5 mM ASECO was incubated in 50 mM Na2HPO4 at pH 7.4 with heat inactivated 
microsomes, 5.0 mM GSH, 5.0 mM MgCl2, and NADPH; 0.5 mM ASECO was incubated in 50 
mM Na2HPO4 at pH 7.4 with 0.5 mg/mL CYP, 5.0 mM GSH, and 5.0 mM MgCl2.  All control 
reactions were performed for 60 min at 37°C and included the addition of salicylamide as per the 
active incubation.  Each reaction was performed in duplicate.   
The HPLC method used for all oxidation experiments utilised a mobile phase of 0.1% 
formic acid in H2O “A”, and 0.1% formic acid in acetonitrile “B”, and was developed as follows: 
95% A for 3 min, decrease to 80% A over 4 min, isocratic for 3 min, decrease to 65% A over 26 
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min, decrease to 10% A over 5 min, isocratic for 4 min, increase to 95% A over 5 min, ending 
run at 50 min.  Volume injection was 150 µL and flow rate was 1.5 mL/min. 
The UPLC-MS method used for oxidation experiments utilised a mobile phase of 1% 
formic acid in H2O “A”, and 1% formic acid in acetonitrile “B”, and was executed as follows: 
95% A initially decreasing to 5% A over 2.60 min, increasing to 95% over 2.08 min, isocratic for 
1.32 min ending run at 6 min.  Volume injection was 10 µL and flow rate was 0.600 mL/min.  
All HPLC and UPLC chromatograms were extracted at λ=280 nm. 
 5.0 RESULTS AND DICUSSION 
The preparation of the lignan analogues for this study was based on the use of 
consecutive Stobbe condensation reactions22.  The benzaldehyde, or benzaldehyde derivative, 
introduced the aromatic functionality, and diethyl succinate provided the alkyl chain of the 
lignan.  Employment of this strategy allowed for the preparation of lignan analogues possessing 
different substituents on the aromatic portions, thus providing a general route to existing and  
novel lignans.  Many of the reactions performed in the synthesis of the lignan analogues 
described in this thesis were carried out several times.  Although small changes were made in an 
effort to improve yield and purity, no systematic optimization of the reaction conditions was 
carried out as the goal of the study was to prepare lignan analogues for in vitro metabolic studies. 
5.1 Pilot Reactions: Eugenol 
 In order to assess the potential reactivity of the four analogues, a number of pilot 
reactions were performed using eugenol, specifically the addition and removal of protecting 
groups to be used during the synthesis of analogues 1 through 4 (Scheme 5-1).  The benzylation 
and hydrogenation of eugenol proceeded as expected; 1H NMR was consistent with the addition 
of a benzyl protecting group to the aromatic hydroxyl group of eugenol following the reaction 
with benzyl bromide.  Hydrogenation of 6 resulted in removal of the benzyl protecting group 
along with saturation of the aliphatic double bond (7) as indicated by 1H NMR.  Finally, removal 
of the methyl ether by way of BBr3 gave the final desired catechol 8, as seen by 1H NMR. 
Demethylation of similar compounds has previously been performed using either (CH3)2S·BBr3 
in CH2Cl2 or BBr3 in CH2Cl214.   In this case, demethylation of the aromatic hydroxyl group was 
originally attempted using the less reactive (CH3)2S·BBr3, but with limited success.  The yield of 
this reaction was found to be 28%, in comparison to the much higher 97% yield obtained using 
BBr3 for the same reaction.  Based on these results, subsequent demethylation reactions were 
carried out using BBr3. 
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Scheme 5-1: Pilot Reactions As Performed with Eugenol 
 
5.2 Synthesis of Analogue 1 
The first Stobbe condensation reaction was carried out in order to prepare the dimethoxy 
phenyl intermediate 9 which would become a component of both analogues 1 and 4 (Scheme 
5-2). This reaction was successfully performed on five different amounts, ranging from 1 g of 
starting material to 5 g of starting material.  The highest yield (62%) was performed using 5 g of 
starting material.  It was anticipated that the benzylic proton of the desired alkene would serve as 
a diagnostic for the formation of the first Stobbe condensation product. 1H NMR showed the 
presence of a benzylic position proton attached to an sp2 hybridized carbon atom at 7.84 ppm, 
which was consistent with the expected alkene. 
 Esterification of the first Stobbe di-carboxylic acid for the synthesis of analogue 1 
(Scheme 5-2) was successfully performed in amounts ranging from 0.4 g to 5 g.  Yields of about 
70% were achieved at smaller scale reactions, but the highest yield (95%) was achieved when the 
reaction was performed using approximately 5 g of starting material.  1H NMR data showed the 
presence of the ethyl groups (1.24, 1.30, 4.14, 4.23 ppm), giving the desired diester. 
 
Scheme 5-2: Partial Synthesis of Analogues 1 and 4 
  
 The second Stobbe condensation reaction (Scheme 5-3), giving an ethyl ester-carboxylic 
acid containing product, was performed on amounts ranging from 0.2 g to 2.4 g.  Yields ranged 
from 58% to 95%, with amounts of 1.4 g of starting material and 2.4 g of starting material giving 
95% yield.  NMR experiments showed the addition of the second aromatic ring, along with the 
presence of a proton attached to the sp2 hybridized carbon atom at the benzylic position of the 
second ring (7.88, 7.92 ppm).  Only one ethyl ester group was present in the NMR spectrum 
(1.13, 4.15 ppm) suggesting that the predicted carboxylic acid 11 was produced. 
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Scheme 5-3: Synthesis of Analogue 1 
 
 Esterification of the carboxylic acid produced from the second Stobbe condensation 
reaction was performed on amounts ranging from 0.20 g to 3.3 g.  Yields ranged from 47% to 
95%, with the yield of 95% performed on 1.8 g of starting material.  NMR showed the presence 
of two ethyl ester groups following this esterification reaction (1.10, 1.15, 4.16 ppm; 10 H). 
The use of two Stobbe condensation reactions was ultimately found to be a successful 
method for producing the basic lignan skeleton.  The configuration of the two double bonds that 
were formed during the synthesis of 1 was not investigated.  However, the 1H NMR shifts of the 
two protons attached to the sp2 hybridized carbon atoms of the double bonds were within less 
than 0.1 ppm of each other.  This is consistent with the double bonds being of the same 
configuration25.  Furthermore, the chemical shift of these olefinic protons were found to agree 
with literature values for similar lignan-like compounds reported as having an E,E 
configuration19, 25, 33, 39, which are typically reported as being downfield of Z olefinic protons in 
similar compounds. 
 Hydrogenation of the two double bonds following esterification was performed in 
amounts ranging from 0.2 g to 1.8 g.  Yields were consistently in the range of 95-98% for all 
reactions.  The absence of the diagnostic downfield sp2 benzylic protons, in addition to the 
presence of a further six protons upfield indicated the hydrogenation was successful. 
Hydrogenation of the diene diester 12 was expected to give four stereoisomers consisting of two 
pairs of enantiomers (Scheme 5-4).  It was expected that some separation of the stereoisomers 
via traditional chromatographic techniques would be possible, however, no separation of the 
stereoisomers of 13 was observed.   
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Scheme 5-4: Hydrogenation of 12 and Potential Stereoisomers 
 
Attempts to selectively synthesize one specific stereoisomer at the point of hydrogenation 
were beyond the scope of this project.  The use of a chiral catalyst could however allow for the 
production of only one stereoisomer at this stage40.  It has been reported that some rhodium and 
ruthenium complexes with chiral phosphines, such as DIPAMP and BINAP are effective for the 
purpose of enantioselective hydrogenation of alkenyl carboxylates, such as 1040.  It is unclear 
what effect if any two such reactive sites in one compound, such as 12, would have on the 
asymmetric hydrogenation reaction.  
LiAlH4 mediated reduction of the diester to the diol was performed in amounts ranging 
from 0.4 g to 0.8 g.  Yields ranged from 26% to 78%, with the highest yield performed at the 
scale of 0.8 g.  The absence of both ethyl ester groups along with the addition of four protons 
consistent with attachment to carbon atoms adjacent to hydroxyl groups (3.50 ppm) suggests the 
desired diol was produced.  Silica gel flash column chromatography resulted in a small degree of 
stereoisomer separation, which was anticipated to be due to two pairs of racemic mixtures, as 
indicated in Scheme 5-4.  Subsequent analysis using reverse phase HPLC showed two product 
peaks that were not baseline separated, thus maintaining a significant amount of overlap.  Further 
attempts to separate the stereoisomers were not carried out at this stage.  Since the lignan diol is 
an analogue to the flaxseed lignan secoisolariciresinol, a small amount of the diol was 
maintained for future studies on secoisolariciresinol analogues. 
 This isomeric mixture then underwent tosylation of the diol to give 15.  Addition of tosyl 
groups to the aliphatic hydroxyl groups was performed in amounts ranging from 0.29 g to 0.6 g.  
Yields ranged from 16% to 40%, with the highest yield of 40% performed at the scale of 0.6 g.  
The addition of two tosyl groups to the diol is seen in the 1H NMR by the presence of eight more 
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 protons in the aromatic region, and six protons present (2.47 ppm) as the aromatic methyl group 
of the tosyl group.  It is notable that following chromatographic purification, the tosylated 
product was found to crystallize within the mobile phase.  The white, needle-like crystals were 
subsequently found to precipitate out of a number of solvent systems readily, including 
petroleum ether, hexane, and ethyl acetate mixtures.  1H NMR data suggest that the crystals 
represent one of the expected racemic mixtures.  This stereochemical resolution was not 
anticipated, but may provide a general method for separation of stereoisomers for other lignan 
analogues. Whether this is a single enantiomer or a single racemic mixture is not known, and 
attempts are currently underway through a collaborator to determine the crystal structure of this 
tosylated product. For the subsequent steps in the synthesis of analogue 1, only these isolated 
crystals were used. 
 Removal of the tosylate via LiAlH4 was performed at 0.7 g and 0.09 g, with yields of 
95% and 90% respectively.  The absence of the aromatic protons attributed to the tosylate 
groups, along with the presence of the aliphatic methyl groups on the connecting carbon chain 
suggested the tosylate groups had been successfully removed. 
 The final step required removal of the methyl groups from the aromatic hydroxyl groups. 
This was performed at the scales of 0.04 g and 0.3 g, with yields of 87% and 92% respectively.  
1H NMR showed the absence of both methyl ether groups indicating that the deprotection was 
successful.  UPLC-MS data was consistent with the preparation of analogue 1.  In summary, 
analogue 1 was successfully synthesized in quantities large enough to continue with the desired 
oxidation reactions. 
5.3 Attempted Synthesis of Analogue 2 
The first step in the synthesis of analogue 2 required the preparation of 4-benzyl-3-
methoxy benzaldehyde, an intermediate that is also required for the preparation of analogue 3.  
Below is a discussion of the results for the preparation of analogue 2, although some of the initial 
Stobbe condensation product was reserved for use in the preparation of analogue 3 (Scheme 5-5). 
 
48 
 
  
Scheme 5-5: Partial Synthesis of Analogues 2 and 3 
 
 The protected benzaldehyde 17 was prepared by the addition of the benzyl protecting 
group to the aromatic hydroxyl group of vanillin in amounts ranging from 6.3 g to 10 g.  Yields 
of 72% to 78% were attained, with the largest yield of 78% achieved at the 6.6 g scale.  1H NMR 
of the final compound showed the addition of five extra aromatic protons, along with the two 
extra benzylic protons (5.18 ppm).  
 The first Stobbe condensation reaction in the synthesis of analogues 2 and 3 was 
performed in amounts ranging from 2.7 g to 9.5 g.  Yields ranged from 63% to 95%, with the 
yield of 95% achieved at the scale of 6.5 g of starting material.  1H NMR showed the presence of 
the diagnostic benzylic proton attached to an sp2 hybridized carbon atom at 7.85 ppm, which was 
consistent with the expected alkene. 
 Esterification of the first Stobbe dicarboxylic acid in the synthesis of analogues 2 and 3 
proceeded in amounts ranging from 3.79 g to 11.9 g.  It was predicted that loss of the benzyl 
protecting group may also result during the acid-catalyzed esterification of 18.  This was found 
to be the case, and both the desired diester 19 and the de-benzylated product 20 were isolated 
from the reaction mixture (Scheme 5-6).  Total yield of both products from the acid-catalyzed 
esterification ranged from 59% to 73%, with the yield of 73% achieved at the scale of 11.9 g of 
starting material.  Benzylation of 20 following the esterification also gave 19 at a yield of 86% 
when starting with 4.6 g of starting material (Scheme 5-6).  1H NMR showed the presence of two 
ethyl ester groups following esterification (1.27, 1.34, 4.19, 4.28 ppm), and five additional 
aromatic protons when the benzyl protecting group was present. 
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Scheme 5-6: Debenzylation of 18 and Subsequent Benzylation of 20 
 
During the scale-up of the synthesis of analogue 2, a base-catalyzed esterification 
reaction was attempted for the conversion of the first Stobbe condensation product 18 to the 
diester (Scheme 5-7).  This reaction was not expected to result in the loss of the benzyl 
protecting group, and was assessed as a faster reaction with a generally higher yield in 
comparison to the acid-catalyzed esterification which would not require the subsequent re-
benzylation step.   
It was found after purification of the major product that the esterification of the two 
carboxylic acid groups was successful, but an additional methylation reaction took place at one 
of the α carbons.  The protons on the saturated α-carbon are sufficiently acidic to result in proton 
abstraction, likely after ester formation has occurred.  The carbanion would then undergo a 
substitution reaction with iodomethane to form the methylated intermediate. Unfortunately this 
product could not be used in the synthesis of analogue 2, but was deemed to be potentially useful 
for the preparation of lignan analogues to SECO and NDGA containing only one aromatic ring. 
Analogues of this nature are of interest to the lab research program and thus the intermediate was 
kept for future use.  As a result of this side-reaction, further attempts to use the base-catalyzed 
esterification with iodomethane at that particular stage of the reaction were not pursued.  
However, it may be that carrying out the reaction under less basic conditions, for example using 
potassium carbonate in place of KOH, may avoid removal of the acidic α-carbon and provide a 
facile route to the esterified intermediate.  Ultimately, the acid-catalyzed esterification coupled 
with the extra benzylation step was left in the reaction scheme. 
 
Scheme 5-7: Attempted Base-Catalyzed Esterification of 18 and Resulting Major Product 
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  The second Stobbe condensation reaction for synthesizing analogue 2 was performed in 
amounts ranging from 1.8 g to 5.4 g of starting materials (Scheme 5-8).  Reaction yields ranged 
from 60% to 97%, with the 97% yield obtained at the scale of 5.4 g.  NMR experiments showed 
the addition of the second aromatic ring, along with the presence of a proton attached to the sp2 
hybridized carbon atom at the benzylic position of the second ring (7.84, 7.91 ppm).  Only one 
ethyl ester group was present in the NMR spectrum (1.12, 4.13 ppm) consistent with the 
formation of the predicted carboxylic acid. 
 
Scheme 5-8: Synthesis of Analogue 2 - Compounds 21, 22 and 23 
 
 Acid catalyzed esterification of the carboxylic acid produced during the second Stobbe 
condensation in the synthesis of analogue 2 gave the benzyl protected diester 22, as well as the 
de-benzylated diester 23.  The reaction was performed with 1.32 g and 3.76 g of starting 
material.  Total yields at these amounts of 22 and 23 combined were 48% and 20% respectively.  
1H NMR of 22 showed the addition of the second ethyl ester following the reaction (δ 1.11, 6H; 
4.17, 4H); compound 23 also showed the addition of the second ethyl ester, along with the 
absence of the benzyl protecting group present in 22. Given that the following step, 
hydrogenation, would result in the loss of the benzyl protecting group, the mixture of compounds 
22 and 23 were put forward together. 
As a result of the continued low yields in the acid-catalyzed esterification of 21, a base-
catalyzed esterification reaction of the carboxylic acid with iodomethane as the methyl source 
was attempted, and was found to be more efficient in that it was a faster reaction, and resulted in 
a higher yield (Scheme 5-9).  The base catalyzed esterification was performed in amounts 
ranging from 4.26 g to 6.51 g, with the highest yield produced at the 4.26 g scale at a value of 
59%.  The lowest yield at 6.51 g was found to be 29%.  1H NMR showed the addition of the 
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 methyl ester group (δ 3.67, 3H) indicating that the desired product had formed.  The base-
catalyzed esterification had the advantage of the benzyl protecting group remaining intact, which 
allowed for purification to take place on only one compound (24), rather than a mixture of the 
benzylated 24 and the de-benzylated diester 23. 
 
Scheme 5-9: Synthesis of Analogue 2 - Compound 24 
 
Hydrogenation of the diester products was anticipated to result in conversion to an alkene 
and hydrogenolysis of the benzyl protecting group (Scheme 5-10). Hydrogenation of the acid 
catalyzed diethyl diester products 22 and 23 was performed twice in the combined amounts of 
0.65 g and 1.13 g.  Both reactions gave yields of 99%, and the final desired product 25 was 
indicated by the absence of the protons attached to the sp2 hybridized carbon atoms present in the 
diene entity, as well as the absence of the benzyl protecting group present in compound 22. 
 
Scheme 5-10: Synthesis of Analogue 2 - Compound 25 
 
Hydrogenation of the base catalyzed ethyl-methyl diester product 24 was performed 
twice, both times at a scale of 2.03 g (Scheme 5-11).  Yields were 99% for both reactions.  1H 
NMR again showed the loss of the distinctive downfield protons attached to the sp2 hybridized 
carbon atoms present in the diene 24, as well as the absence of the benzyl protecting group also 
present in compound 24.  As was the case with analogue 1, no separation of the four expected 
stereoisomers via traditional chromatographic techniques was seen following the hydrogenation 
of the diene entities to compounds 25 or 26. 
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Scheme 5-11: Synthesis of Analogue 2 - Compound 26 
 Reduction of both esters 25 and 26 with LiAlH4 gave diol 27 as indicated by the absence 
of the ester groups in the 1H NMR of the final product (Scheme 5-12).  The diethyl ester 25 was 
reduced to the diol twice at amounts of 0.66 g and 0.83 g, with yields of 46% and 25% 
respectively.  The ethyl-methyl ester 26 was reduced to the desired diol twice at amounts of 1.42 
g and 1.39 g.  Yields for these reactions were 23% and 42% respectively.  As was the case for 
analogue 1, the mixture of stereoisomeric diols (27) could not be adequately separated via flash 
column chromatography and the mixture was carried forward for subsequent reactions. 
 
 Scheme 5-12: Synthesis of Analogue 2 - Compounds 27, 28, and 29 
 
Tosylation of the hydroxyl groups of 27 (three in total) was performed in amounts of 0.26 
g and 0.49 g, with yields of 30% and 36 % respectively.  The formation of the tosylated lignan 
once again resulted in the formation of a precipitate that allowed for the separation of what 
appeared to be one pair of enantiomers.  This assessment was made based mainly on 1H NMR 
evidence.  The mixture obtained prior to the flash column contained what appears to be two sets 
of aliphatic 1H NMR signals that are consistent with the aliphatic portion of the lignan; however 
the purified white solid contains only one of these sets of signals.    
 Reduction of the aliphatic tosylate groups using LiAlH4 was performed once in the 
amount of 53.7 mg of starting material giving a yield of 72%.  1H NMR confirmed the loss of 
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 two tosylate groups from 28, showing the expected aliphatic methyl groups, but indicated the 
aromatic tosylate group remained, as shown by the expected four aromatic and three methyl 
protons.  A second attempted detosylation reaction performed at the scale of approximately 440 
mg was unsuccessful as a large number of side products were formed during this reaction.  1H 
NMR spectra obtained from the results of this reaction showed signals, integrals and chemical 
shifts with both starting material and desired product.  Virtually no usable product was isolated. 
 One attempt was made to remove the aromatic tosylate group (Scheme 5-13), which 
would have given the final compound 2.  This was performed by refluxing approximately 20 mg 
of 29 in 20% NaOH solution and methanol37.  1H NMR of the crude product showed that the 
tosylate group had been successfully removed from the aromatic ring.  It was expected that one 
signal would be present at approximately 3.8 ppm with an integral of 3 corresponding to the 
aromatic methyl ether present in compound 2.  It was found, however, that two signals were 
present at 3.85 ppm and 3.89 ppm, both integrating to approximately 2. 
 
 
Scheme 5-13: Attempted Synthesis of Final Product Analogue 2 
 TLC showed what appeared to be two products.  An attempted separation of the two 
products was performed via PTLC.  1H NMR of the two separated products showed some degree 
of purification; in particular, one spectrum showed a higher intensity signal at 3.85 ppm 
compared to 3.89ppm, and the other spectrum showed a higher intensity signal at 3.89 ppm 
compared to 3.85ppm.  It was also noted that the one of the two separated products (lower Rf) 
turned yellow prior to being scraped off the PTLC plate. 
 On comparing the 1H NMR spectrum of the crude product with compound 16, the 
dimethoxy compound in the synthesis of 1, it was found that they were virtually identical.  In 
particular, the two aromatic methyl ether signals of compound 16 were found at 3.85 ppm and 
3.89 ppm in the 1H NMR spectrum.  Based on this evidence, it was theorized that an 
intramolecular methyl transfer reaction had potentially taken place, and the final product of the 
attempted detosylation reaction was a mixture of methoxy phenol products (Figure 5-1).  It was 
also thought that the compound possessing the lower Rf value was likely the para phenol due to 
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 the observation that quinones often turn yellow on oxidation (personal communication, E.S. 
Krol) 
 
Figure 5-1: Potential Product Mixture following Attempted Detosylation of 29 
 
 It is unclear exactly what caused this unusual result.  Following the unsuccessful second 
attempt to remove the alkyl tosylate groups with LiAlH4, it was determined that further 
investigation was warranted, and the solutions to these issues were likely beyond the scope of 
this project.  One possible future direction for solving the problem of removing the aromatic 
tosylate could involve adding a tosyl group to a eugenol analogue such as compound 7 and 
attempting to remove it using NaOH solution and methanol as per literature procedures. 
5.4 Attempted Synthesis of Analogue 3 
 The second Stobbe condensation for the synthesis of 3 was performed once at the scale of 
2.62 g of starting material 19, giving a yield of 41% (Scheme 5-14).  1H NMR showed the 
addition of the second benzaldehyde unit, including the eight additional protons found in the 
aromatic region of the spectrum, and the integration of the signal corresponding to the protons 
attached to the sp2 hybridized carbon atoms as two protons (δ 7.76). 
 
Scheme 5-14: Partial Synthesis of Analogue 3 
 
The carboxylic acid 30 produced from the second Stobbe condensation reaction in the 
synthesis of analogue 3 was found to be highly insoluble in most common solvents, including 
ethanol.  This made the acid-catalyzed esterification step performed on analogues 1 and 2 
essentially impossible, and another method was required to produce the ester.  After determining 
that the acid was soluble in DMSO, which was utilized for obtaining 1H and 13C NMR spectra, a 
second esterification reaction was identified in the literature as potentially useful36.  This reaction 
was performed in DMSO, along with KOH and CH3I.  This method would give the methyl ester 
as opposed to the ethyl ester, but the diol produced following hydrogenation and LiAlH4 
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 reduction of the diester would be identical.  The base-catalyzed esterification of the carboxylic 
acid was performed once in the amount of 168 mg and produced a higher yield (96%) with fewer 
impurities and a shorter reaction time when compared to its analogue 1 and 2 counterparts.  1H 
NMR showed the successful esterification of the carboxylic acid by the addition of the methyl 
group at δ 3.70.  The base-catalyzed esterification was incorporated into the schemes for the 
synthesis of analogues 1 and 2 during scale-up of these products and has been outlined in 
previous sections. 
 1H NMR of compounds 30 and 31 showed only one signal integrated to two protons, 
corresponding to the olefinic hydrogen atoms.  Despite the presence of the carboxylic acid group 
in compound 30, this is likely due to the symmetrical nature of analogue 3.  Given that it has 
been reported in the literature that protons in similar compounds (i.e.  alkenes or dienes that are 
the result of a single or double Stobbe condensation reaction) show significantly different 
chemical shifts in an E configuration versus a Z configuration25, 33, 39, it is expected that these two 
double bonds have the same configuration.   
 Due to time constraints, analogue 3 was never pursued beyond this diester entity. 
5.5 Attempted Synthesis of Analogue 4 
 The benzylation of dihydroxybenzaldehyde was performed once in the amount of 5.03 g 
of starting material (Scheme 5-15).  The final yield was found to be 11%.  1H NMR showed ten 
extra signals in the aromatic region of the spectrum indicating the reaction was successfully 
performed. 
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Scheme 5-15: Partial Synthesis of Analogue 4 
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  The second Stobbe condensation reaction in the synthesis of analogue 4 was performed 
once with 1.30 g of benzaldehyde.  The yield for this reaction was found to be 53%.  1H NMR 
showed the expected carboxylic acid from a Stobbe condensation reaction, including the two 
protons attached to the sp2 hybridized carbon atoms (δ 7.40). 
 The carboxylic acid 33 formed during the second Stobbe condensation reaction in the 
synthesis of analogue 4 was found to be as equally insoluble as its analogue 3 counterpart.  
Following the success of the base-catalyzed esterification of 30 performed in DMSO in the 
synthesis of analogue 3, the base-catalyzed esterification of 33 was performed once on a scale of 
1.01 g of starting material, giving a yield of 56%.  1H NMR showed the addition of the methyl 
group to the carboxyl group at δ 3.89. 
 Hydrogenation of the diene diester entity 34 was performed once with 0.56 g of starting 
material.  The final yield of this reaction was found to be 98%.  The loss of the downfield sp2-
attached proton signals, along with the absence of the ten aromatic region protons indicative of 
benzyl protecting groups in the 1H NMR indicated the reaction was performed successfully.  No 
attempts were made to separate the stereoisomers that presumably formed during the reaction.  
Due to time limitations, the synthesis of analogue 4 was not pursued beyond the hydrogenation 
step. 
5.6 Incubation of 1 in Rat Liver Microsomes 
 The incubation of analogue 1 in rat liver microsomes was performed on two separate 
occasions.  The first set of experiments was analyzed by HPLC only.  Analysis of the resulting 
data showed that analogue 1 eluted at Rt=42.4 min, and salicylamide was found to elute at 
Rt=11.3 min  The presence of a small amount of impurity present in the analogue 1 sample, 
which eluted at Rt=43.2 min, was also observed.   
 Given that the di-catechol NDGA autoxidizes at pH 7.4 over the one hour incubation 
time in the presence of active microsomes in phosphate buffer alone11, the possibility of similar 
autoxidation activity in the mono-catechol 1 was not discounted.  The fact that NDGA 
autoxidizes faster than a number of other catechols, such as catechol and dopamine11, does 
suggest however that autoxidation rates would be significantly lower for analogue 1. 
 In the absence of active microsomes, no product formation occurred (Figure 5-2), and 
there was no apparent decrease in the area of the HPLC peak for 1.  This was the case in only 
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 buffer, in the presence of heat inactivated microsomes, and in the absence of NADPH.  The 
absence of autoxidation implies that rapid autoxidation of a lignan such as NDGA requires 
substitution on both aromatic rings. 
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Figure 5-2: HPLC-UV (280 nm) Chromatogram of 1 Following 1 h Incubation in the Absence of Active 
Microsomes  
  
   The incubation of analogue 1 in active microsomes was expected to result in the 
formation of an o-quinone.  In the presence of glutathione, it follows that the electrophilic o-
quinone would be trapped by the nucleophilic tripeptide.   
 Incubation of 1 without GSH resulted in the formation of one product eluting at Rt=40.7 
min with the analytical method developed for the Waters Alliance HPLC system (Figure 5-3).  
Incubation in the presence of GSH also gave the 40.7 min product, as well as another product 
eluting at Rt=35.4 min (Figure 5-4).  The major component of the mixture following the 
incubation experiments continued to be analogue 1, but of the two products formed, the 35.4 min 
peak was estimated to be present in larger amounts based on the absorbance units measured by 
the HPLC.   
 
Figure 5-3: HPLC-UV (280 nm) Chromatogram of 1 Following 1 h Incubation in the Presence of Active 
Microsomes; no GSH. 
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Figure 5-4: HPLC-UV (280 nm) Chromatogram of 1 Following 1 h Incubation in the Presence of Active 
Microsomes plus GSH 
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 The second set of incubation data obtained was analyzed by HPLC and by UPLC-ESI-
MS(-).  When the incubation performed in the presence of GSH was analyzed via UPLC-MS, the 
product peaks were found to elute at 1.2 min with m/z 879.2, and 1.5 min with m/z 574.2.  The 
experimental mass of 574.2 corresponds to analogue 1 plus one unit of GSH.  This result is 
unexpected as this product was observed in the absence of GSH.  It is possible, however, that 
some endogenous GSH was present in the isolated rat liver microsomes.  The experimental mass 
of 879.2 corresponds to analogue 1 plus two units of GSH.   
 The addition of GSH to analogue 1 suggests the formation of an electrophilic entity, such 
as an o-quinone, via oxidation by P450 enzymes present in the rat liver microsomes.   
5.7 Oxidation of 1 with Mushroom Tyrosinase 
 The oxidation of analogue 1 using mushroom tyrosinase was expected to result in the 
formation of the o-quinone form of the catechol 11, 12, 14.  Addition of GSH to the oxidation 
reaction would result in the o-quinone being trapped with GSH.  Similar experiments performed 
on NDGA resulted in the formation of the o-quinone, and three different NDGA-GSH adducts 
were isolated and identified 11. 
 The oxidation experiment of 1 with mushroom tyrosinase in the absence of glutathione 
showed no product formation.  In the presence of glutathione, added at t=0 min of the reaction, 
and at t=60 min of the reaction, three product peaks were observed via HPLC as follows: 
Rt=34.9 min, Rt=40.3 min, and Rt= 41.0 min (Figure 5-5). 
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Figure 5-5: Oxidation of 1 with Mushroom Tyrosinase; GSH Present 
 
 The major product was found by UPLC-ESI-MS(-) to have a m/z 574.1 eluting at 1.5 min  
This corresponds to analogue 1 plus one GSH, and also corresponds to one of the products 
formed during the incubation of 1 in rat liver microsomes.   
 One of the minor products formed in the oxidation of 1 via mushroom tyrosinase was 
found to elute at 1.2 min with m/z 879.2.  This corresponds to 1 plus two GSH, and is consistent 
with the product formed during the incubation of 1 in rat liver microsomes.  A third product was 
formed during the tyrosinase oxidation which eluted at 1.4 min with m/z 731.3.  Based on the 
recorded UV absorbance units, it appears that only a small amount of this product formed.  The 
mass does not correspond to any of the products formed during the microsomal incubation. 
 It appears that the major product m/z 574.2 is formed in sufficient quantities to allow for 
the collection of this product, however it is unlikely that mushroom tyrosinase oxidation would 
allow for the collection of the secondary product m/z 879.2.  Investigation into the structure of 
this 1-GSH adduct via NMR may provide more information as to the nature of the electrophilic 
moiety formed on mushroom tyrosinase and P450-mediated oxidation.  The position at which the 
GSH bonds with the compound could potentially confirm the formation of the o-quinone. 
5.8 Oxidation of 1 with Silver Oxide 
 The oxidation of analogue 1 with silver oxide was predicted to give a p-QM, as is 
commonly seen in catechols12, 14, 38, 41.  In the case of NDGA, Ag2O failed to produce the p-QM, 
and no GSH reactive products were ever isolated.  The oxidation of analogue 1 with Ag2O both 
in the absence (Figure 5-6) and presence (Figure 5-7) of GSH showed multiple product peaks via 
HPLC.  The major product in the presence of GSH appears to be consistent with the major peak 
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 formed during oxidation with mushroom tyrosinase, which was ultimately found to correlate 
with 1-GSH.  Given the multiple product peaks that were present which did not correspond to 
peaks present in either the mushroom tyrosinase oxidation, or the microsomal incubation, the 
oxidation of 1 via Ag2O was not pursued any further. 
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Figure 5-6: Ag2O Oxidation of 1 in the Absence of GSH 
 
 
Figure 5-7: Ag2O Oxidation of 1 in the Presence of GSH 
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5.9 Oxidation of 1 with Horseradish Peroxidase 
In an effort to find a method which would allow for the isolation of product m/z 879.2, 
analogue 1 was oxidized with horseradish peroxidase.  It was found that the major product was 
in fact the desired peak at Rt=35.3 min (Figure 5-8), and HPLC chromatograms showed excellent 
baseline separation between the desired product, and the other components of the reaction 
mixture.  A further six products were seen via HPLC, none of which appeared to correspond to 
any of the products seen in the other oxidation experiments.   
 Isolation of the major product from the horseradish peroxidase oxidation experiment 
would allow for the investigation of the structure of this adduct via NMR.  Determination of the 
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 location of the GSH molecules on the lignan would provide information regarding the nature of 
the electrophilic entity produced during oxidation of 1 via rat liver microsomes, mushroom 
tyrosinase, and horseradish peroxidase. 
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Figure 5-8: Oxidation of 1 with Horseradish Peroxidase with GSH 
 
5.10 Incubation of ASECO in Rat Liver Microsomes 
The structure of ASECO closely resembles that of analogue 3.  Consequently, ASECO was 
incubated in the presence of rat liver microsomes in an effort to better predict the formation of an 
electrophilic entity from analogue 3.  Control reactions performed at pH 7.4, including heat 
inactivated microsomes and microsomes with no NADPH present showed no product formation.  
HPLC results showed product formation as a peak at Rt=22.2 min for the active incubation in the 
presence of GSH (Figure 5-9).  The peak present at Rt=32.8 was identified as ASECO.  UPLC-
MS showed product at Rt=1.1 min, with a m/z 648.2 in MS-ESI(-).  This corresponds to ASECO 
plus one GSH. 
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Figure 5-9: Close-up of HPLC Results from ASECO Incubation in Rat Liver Microsomes with GSH 
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Given the structure of ASECO, it is likely that it was oxidized to the p-QM, which was 
then trapped with GSH (Scheme 5-16).  This theory could be tested by oxidizing ASECO with 
Ag2O in the presence of GSH.  In the case that the same product was found as that present in the 
microsomal incubation, the reaction could be performed in sufficient quantities to collect the 
product for NMR. 
 
Scheme 5-16: Oxidation of ASECO and Subsequent Trapping with GSH 
 
The fact that ASECO formed an electrophilic product during the microsomal incubation 
suggests that analogue 3 could potentially form a similar product under similar conditions.  The 
similar substitution pattern of one of the aromatic rings (i.e. para-phenol) of 2 also suggests the 
possibility for the formation of an electrophilic intermediate on oxidation of analogue 2. 
 
 6.0 SUMMARY AND CONCLUSIONS 
The attempted synthesis of the four structural analogues of NDGA ultimately consumed 
the majority of the time devoted to this project.  The double Stobbe condensation reaction was 
found to provide sufficient flexibility for the synthesis of a variety of substituted lignan 
skeletons.  Furthermore, the reactions reported by Xia et al.22 in the synthesis of NDGA were 
found to be successful in the synthesis of the desired mono-catechol analogue 1.   
Following the successful synthesis of 1, the determination of the metabolites formed 
during incubation in rat liver microsomes was investigated.  Oxidation of analogue 1 in the 
presence of rat liver microsomes produced an electrophilic metabolite which reacted with GSH.  
UPLC-ESI-MS(-) found the products to have m/z 574.2, and m/z 879.2, which is consistent with 
1 + GSH, and 1 + 2GSH respectively.  The absence of product formation during control 
incubations confirmed that the autoxidation of 1 at pH 7.4 is significantly slower than that of 
NDGA. 
In order to determine the identities of the products formed during the microsomal 
incubation, the oxidation of analogue 1 using enzymatic and chemical methods was carried out.  
Mushroom tyrosinase, which is known to produce o-quinone moieties in catechols14 gave a 
major product with m/z 574.2, apparently identical to that of the product found with incubation in 
rat liver microsomes.  A small amount of product with m/z 879.2 was also found.  It is likely that 
the o-quinone did form, however further investigation is required to confirm.   
Oxidation of analogue 1 with silver oxide resulted in some product corresponding to m/z 
879.2, but most products were inconsistent with the results from the rat liver microsomes 
oxidation.  It is unclear whether this reaction produced a p-QM.  Oxidation of analogue 1 with 
horseradish peroxidase was found to produce significant amounts of the product possessing a 
retention time consistent with that of the product with m/z 879.2.  Finally, incubation of ASECO 
in rat liver microsomes was found to give a product of m/z 648.2, which is consistent with 
ASECO + GSH, indicative of p-QM formation. 
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7.0 FUTURE DIRECTIONS 
Completion of the synthesis of analogues 2, 3, and 4 will be needed to obtain a complete 
set of oxidation data for these structural analogues.   
With the major metabolites of analogue 1 during incubation in rat liver microsomes 
identified via HPLC and UPLC-MS, the next challenge is the synthesis of these metabolites, 
potentially via mushroom tyrosinase and horseradish peroxidase.  Once sufficient quantities of 
these products have been produced, determination of the structure of these GSH adducts can then 
be performed via NMR studies.  The position at which GSH binds to analogue 1 should help in 
identifying the nature of the electrophilic entity which formed during the metabolism 
experiments.  Investigation into the autoxidation potential of 1 could also be performed by way 
of a pH rate profile. 
Other potential directions for this project include the synthesis of other analogues of 
NDGA and naturally occurring lignans, such as ASECO.  Potential biological or 
pharmacological activity of these compounds, such as anti-viral activity or in vitro inhibition of 
P450 could also be assessed. 
Another interesting question that may be addressed is the mechanism of the NDGA 
autoxidation reaction.  The previous observation of NDGA autoxidation to the 
dibenzocyclooctadiene was suggested to occur via a radical reaction (Scheme 8-1)11, but could 
also occur as the result of an electrophilic addition (Scheme 8-2)42. 
 
Scheme 8-1: Cyclization of NDGA to the Dibenzocyclooctadiene via a Radical-Mediated Reaction 
 
  
Scheme 8-2: Cyclization of NDGA to the Dibenzocyclooctadiene via an Electrophilic Addition Reaction 
 
Analogue 1 could only undergo a similar type of cyclization via an electrophilic addition 
since it does not possess a readily ionizable -OH on the unsubstituted ring (Scheme 8-3).  Thus, 
analogue 1 could undergo autoxidation, although it must occur at a greatly reduced rate.  The 
Hammett σ value for H = 0.0, and for OH is -0.37 (para) and 0.12 (meta)43, which would suggest 
that the catechol-substituted aromatic ring in NDGA is more nucleophilic than the unsubstituted 
ring in analogue 1.  If autoxidation were to occur through an electrophilic addition reaction as 
described in schemes 8-2 and 8-3, then analogue 4 (OCH3, Hammett σ = -0.27 (para) and 0.12 
(meta)) would be anticipated to undergo autoxidation at a rate closer to that observed for NDGA. 
Analogue 4 cannot undergo a radical-mediated reaction as outlined in scheme 8-1, therefore the 
absence of autoxidation in analogue 4 could imply that a radical-mediated process more 
accurately describes NDGA oxidative cyclization. 
 
Scheme 8-3: Cyclization of Analogue 1 to a Dibenzocyclooctadiene via an Electrophilic Addition Reaction 
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